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• What is preemptive analgesia?The classic definition of 
preemptive analgesia requires two groups of patients to 
receive identical treatment before or after incision or 
surgery. The only difference between the two groups is 
the timing of administration of the pharmacological 
agent relative to incision. The constraint to include a 
postincision or postsurgica I treatment group is 
methodologically appealing, because in the presence of 
a positive result, it provides a window of time within 
which the observed effect occurred, and thus points to 
possible mechanisms underlying the effect: the classic 
view assumes that the intraoperative nociceptive 
barrage contributes to a greater extent to postoperative 
pain than does the postoperative nociceptive barrage. 
However, this view is too restrictive and narrow in part 
because we know that sensitization is induced by 
factors other than the peripheral nociceptive barrage 
associated with incision and subsequent noxious 
intraoperative events. 
• What is preventive analgesia? A broader approach to 
the prevention of postoperative pain has evolved that 
aims to minimize the deleterious immediate and long-
term effects of noxious peri operative afferent input. The 
focus of preventive analgesia is not on the relative 
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timing of analgesic or anesthetic interventions, but on 
attenuating the impact of the peripheral nociceptive 
barrage associated with noxious preoperative, 
intraoperative, and/or postoperative events/stimuli. 
These stimuli induce peripheral and central sensitization 
which increase postoperative pain intensity and 
analgesic requirements. Preventing sensitization will 
reduce pain and analgesic requirements. Preventive 
analgesia is demonstrated when postoperative pain and/ 
or analgesic use are reduced beyond the clinical 
duration of action of the target agent which we have 
defined as 5.5 half-lives of the target agent This 
requirement ensures that the observed effects are not 
analgesic effects. 
• What does the recent preemptive analgesia literature 
tell us? The results of the present literature review 
indicate that the proportion of significant preemptive 
effects (0.63) is not significantly different from the 
proportion of negative preemptive effects (0.37) across 
the different classes of drugs studied (p= 0.36). This is 
understandable when one considers that both 
preincisional and postincisional (or postsurgical) noxious 
inputs contribute to postoperative sensitization, pain, 
and analgesic consumption. The most likely conclusion, 
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therefore, is that for a certain proportion of studies of 
preemptive analgesia, the postincision or postsurgical 
administration condition is as beneficial in reducing 
central sensitization as is the preoperative condition, 
but these benefits go undetected when the comparison 
is made between the two groups. The lack of a control 
group in studies of preemptive analgesia is a serious 
limitation that confounds interpretation of the results 
and has contributed to the premature and erroneous 
conclusion that there is no clinical benefit to 
preoperative nociceptive blockade. 
• What does the recent preventive analgesia literature 
tell us? In contrast to the results for preemptive 
analgesia, the proportion of significant preventive 
effects (0.72) is significantly greater than the proportion 
of negative effects (0.28) across the different classes of 
drugs studied (p = 0.03). Overall, administration of these 
agents appears to reduce pain, analgesic consumption, 
or both at a point in time that exceeds 5.5 half-lives of 
the target agent. Since these extended effects are 
BACKGROUND LITERATURE 
Acute postoperative pain management has been domi-
nated by an outdated concept of pain. Pain is viewed as 
the end product of a passive system that faithfully trans-
mits a peripheral "pain" signal from receptor to a "pain 
centre" in the brain. I This view has resulted in a strategy 
for managing postoperative pain that is inadequate, in 
part, because it treats the patient only after the pain is well 
established. Patients arrive in the post-anesthetic care unit 
after surgery, often in extreme pain, where they then 
receive multiple doses of opioids in an effort to bring the 
pain down to a tolerable level. However, basic science and 
clinical data show that brief, noxious inputs or frank 
injury due to C-fiber activation (e.g. cutting tissue, nerve, 
and bone) induce long-lasting changes in central neural 
function that persist well after the offending stimulus has 
been removed or the injury has healed.2,3 This view of 
pain, involving a dynamic interplay between peripheral 
and central mechanisms, is inconsistent with the outdated 
notion that pain results from transmission of impulses 
along a straight-through pathway from the site of injury 
to the brain. I 
The practice of treating pain only after it has become 
well entrenched is slowly being supplanted by a preventive 
approach that aims to block transmission of the primary 
afferent injury barrage before, during, and after surgery.4.5, 
6,7 The idea behind this approach is not simply that it 
reduces nociception and stress during surgery - although 
these are obviously worthwhile goals. The hypothesis is that 
the transmission of noxious afferent input from the per-
iphery arising from preoperative pain, incision, 
observed after the clinical actions of the agents have 
worn off, they are not analgesic effects. Rather, these 
effects appear to be due to the reduction in 
perioperative peripheral and central sensitization 
associated with preventive analgesia. The benefits of 
preventive analgesia are clinically relevant and include 
reduced pain and/or analgesic consumption that extend 
beyond the duration of action of the target drug. 
• What other important factors da we need to measure 
perioperatively? Measures of postoperative pain and 
analgesic use are important, but given the prominent 
role played by psychosocial factors in the experience of 
preoperative, acute postoperative, and chronic 
postsurgical pain, relevant psychological, emotional, and 
physical variables should be routinely assessed before 
and after surgery. Assessment of the'Se additional 
domains of functioning may help to shed light on the 
predictors of severe acute postoperative pain, the 
processes involved in recovery from surgery, and the risk 
factors for developing chronic postsurgical pain. 
noxious intraoperative events, postoperative inflammation, 
and ectopia) to the spinal cord induces a prolonged state of 
central neural sensitization or hyperexcitability that ampli-
fies subsequent input from the wound and leads to 
heightened postoperative pain and a greater requirement 
for postoperative analgesics. By interrupting the transmis-
sion of the peripheral nociceptive barrage to the spinal cord 
at various points in time throughout the perioperative 
period, a preventive approach aims to block the induction 
of central sensitization, resulting in reduced pain intensity 
and lower analgesic requirements. goal of this chapter 
is to critically review the recent literature on preemptive 
and preventive analgesia. The first section provides a 
description of the perioperative targets of a preventive 
analgesic approach. This is followed by a brief review of the 
factors that have been shown to predict the development of 
acute and chronic postsurgical pain. Next, the history and 
recent progress in preemptive analgesia are presented with 
emphasis on the confusion and lack of clarity that char-
acterizes the field. Under Controversy and confusion about 
preemptive analgesia, we attempt to clear up the confusion 
by highlighting clinical trial designs and examples from the 
literature that distinguish preventive analgesia from pre-
emptive analgesia. This is followed by a quantitative review 
of the preemptive and preventive analgesia literatures (see 
below under Preventive analgesia), organized according to 
class of drug administered. Outcomes are described in 
terms of the presence or absence or a preemptive or pre-
ventive effect and a detailed tabular summary is presented 
of all studies that met our criteria for inclusion in the 
review. The chapter concludes with recommendations for 
future research. 
TARGETS OF A PREVENTIVE APPROACH TO 
ACUTE PAIN MANAGEMENT 
The perioperative period can be divided into three distinct 
phases: preoperative, intraoperative, and postoperative 
(Figure 9.1). Specific factors within these phases con-
tribute to the development of acute postoperative pain. 
These factors include: (1) preoperative noxious inputs and 
pain; (2) C-fiber injury barrage arising from the cutting of 
skin, muscle, nerve and bone, wound retraction, etc.; and 
postoperative peripheral nociceptive activity, including 
that arising from the inflammatory response and ectopic 
neural activity in the case of postsurgical nerve injury. Each 
of these factors can contribute to peripheral and central 
sensitization and each is a legitimate target for a preventive 
approach. The relative contribution of these three factors 
to acute postoperative pain is dependent on the surgical 
procedure, extent and nature of tissue damage, duration of 
surgery, timing of treatments relative to incision, phar-
macokinetics of the agent(s) used preoperatively, presence 
or absence of additional analgesia intraoperatively, nature 
of postoperative analgesia, and a host of other variables. 
Minimizing the negative impact of as many of these factors 
as possible in the three phases will increase the likelihood 
of preventing the induction and maintenance of peripheral 
and central sensitization. Preventing sensitization will 
reduce pain and analgesic requirements. 
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Figure 9.1 depicts the eight possible treatment com-
binations of administering or not administering analge-
sics across the three peri operative phases (preoperative, 
intraoperative, and postoperative). The preoperative 
period encompasses interventions that begin days before 
surgery and up to those administered just minutes before 
skin incision. The intraoperative period includes inter-
ventions started immediately after incision to those 
initiated ,iust prior to the end of surgery (i.e. skin closure). 
The postoperative period includes interventions started 
immediately after the end of surgery and may extend for 
days or weeks thereafter. Within each phase there is 
potential for extensive variability in the timing of 
administration of analgesic agents. While this potential is 
greatest in the pre- and postoperative phases (e.g. ranging 
from minutes to days or weeks) even within the intrao-
perative period, evidence shows that there are consider-
able interstudy differences in timing of the postincisional 
intervention (e.g. ranging from minutes to hours). 
PREDICTORS OF ACUTE AND CHRONIC 
POSTSURGICAL PAIN 
The ability to predict who will develop severe acute 
postoperative pain and who will go on to develop chronic 
postsurgical pain is at the heart of efforts to understand 
Figure 9.1 Schematic representation showing 
the administration (+) or non-administration (-) 
of analgesic agents across the three perioperative 
phases of surgery (preop, preoperative; intraop, 
intraoperative; postop, postoperative). The 
administration or nonadministration of analgesics 
during the three phases yields eight different 
treatment combinations and 28 possible two-
group designs to evaluate the efficacy of 
preemptive and preventive analgesia. The classic 
preemptive analgesia design requires two groups 
of patients to receive identical treatment before 
or after incision or surgery (treatment 
combination 2 versus 3 and 2 versus 4). This 
represents only one of many possible hypotheses 
concerning the effects of blocking noxious 
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llme analgesic consumption. 
the role played by the various factors within the three 
perioperative phases depicted in Figure 9.1. One of the 
most robust findings to emerge from the postoperative 
pain and anesthesia literatures is that current pain pre-
dicts future pain.8, 9, 10, II This appears to be true across 
surgery types and regardless of time frame. Preoperative 
pain intensity or pain duration is a risk factor for devel-
opment of severe early acute postoperative pain,12 acute 
pain days, 13, !4,15, 16, 17 and weeks!8 after surgery, as well 
as long-term postsurgical pain.14, 15, 18, 19,20,21,22 Pre-
pain ratings in response to the cold pressor 
suprathreshold heat pain stimuli,24 and a first-
burn injury25 also acute postoperative pain 
intensity days after surgery. Severity of acute post-
operative pain not only pain after discharge, 18.26 
but it is also a risk factor for development of chronic 
postsurgical pain.27, 28, 29,30.31,32 
No other factor is as consistently related to the devel-
opment of future pain problems as is current pain, Younger 
age,12, 18 female gender,12, 18 anxiety,12, 19 and various other 
psychological variables8, 33, 34, 35, 36 predict postoperative 
pain in some studies, but not with the consistency or 
magnitude with which pain predicts pain. What must be 
determined is the aspect(s) of pain that is predictive, Is it 
something about the pain per se (e.g. intensity, quality, 
duration) or the individuals who report the pain 
response bias, psychological vulnerability, genetic predis-
position)? Will reducing surgery-induced sensitization alter 
the course of acute pain and lead to a decreased incidence 
of long-term pain problems? What factors are responsible 
for the transition of acute postoperative pain to chronic, 
intractable, pathological pain? We do not have answers to 
these important questions but one of the factors that has 
been linked to increased pain and analgesic consumption 
in the short and long term is the perioperative peripheral 
nociceptive injury barrage associated with surgery, The 
remainder of tillS chapter will focus on an evidence-based 
presentation of the literature that examines the efficacy of 
preemptive and preventive interventions aimed at reducing 
surgically induced sensitization. 
HISTORY AND RECENT PROGRESS IN 
PREEMPTIVE ANALGESIA 
The idea that acute postoperative pain might be intensi-
fied by a state of central neural hyperexcitability induced 
during surgery was first proposed by Crile (see Katz37 ) 
and later by Wa1l38 who suggested that "preemptive pre-
operative analgesia" would block the induction of central 
neural sensitization brought about by incision and thus 
reduce acute postoperative pain intensity. Since its 
introduction into the pain and anesthesia literatures, this 
concept has been refined, based in part on confirmatory 
and contradictory evidence from clinical studies, new 
developments in basic science, and critical thought. 
The suggestion that surgical incision triggered central 
sensitization38 has been expanded to include the sensi-
tizing effects of preoperative noxious inputs and pain, 
other noxious intraoperative stimuli, as well as post-
operative peripheral and central inflammatory mediators 
and ectopic neural activity. 
It is now well documented that while general anes~ 
thesia may attenuate transmission of afferent injury bar-
rage from the periphery to the spinal cord and brain, it 
does not block it.39 Moreover, systemic opioids may not 
provide a sufficiently dense blockade of spinal nociceptive 
neurons to prevent central sensitization.40 The clinical 
significance of these findings for patients who receive 
general anesthesia during surgery is that although they are 
unconscious, the processes leading to sensitization of 
dorsal horn neurons are largely unaffected by general 
anesthesia or routine doses of opioids. This sets the stage 
for heightened postoperative pain and an increased 
requirement for analgesics. 
CONTROVERSY AND CONFUSION ABOUT 
PREEMPTIVE ANALGESIA 
Debate over the appropriate definition of preemptive 
analgesia5• 6,41,42,43,44,45,46,47 has spawned a variety of 
different terms, including anoci-association/8 preemptive 
preoperative analgesia,38 preemptive analgesia,49 pre-
ventive analgesia,4, 6 balanced periemptive analgesia, 50 
broad versus narrow preemptive analgesia,S! and protec-
tive analgesia. 52 Substantial confusion has developed over 
the benefits and meaning of preemptive analgesia. 
Two general approacHes have dominated the litera-
ture.53 The classic view of preemptive analgesia49 requires 
two groups of patients to receive identical treatment 
before or after incision or surgery (treatment combina-
tion 2 versus 3 and 2 versus 4 in Figure 9.1), Accordingly, 
the only difference benlTeen the two groups is the timing 
of administration of the pharmacological agent relative to 
incision with one group receiving the target agent before 
surgery, and the other, after incision or surgery (see 
Figures 9.2 and 9.3 depicting studies by Katz et ai.54 and 
Dierking et al.55 who used these designs, respectively), 
The constraint to include a postincision or postsurgical 
treatment group is methodologically appealing because in 
the presence of a positive result, it provides a window of 
time within which the observed effect occurred and thus 
points to possible mechanisms underlying the effect. 
However, this view of preemptive analgesia is too 
restrictive and narrow5, 6, 56 in part because we do not 
know the relative extent to which pre-, intra-, and post-
operative peripheral nociceptive inputs contribute to 
central sensitization and postoperative pain. 
The narrow conceptualization of preemptive analgesia 
in conjunction with the classic pre- versus postsurgery 
design assumes that the intraoperative nociceptive barrage 
contributes to a greater extent to postoperative pain than 
does the postoperative nociceptive barrage, However, the 
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Figure 9.2 Experimental design and expected postoperative outcome for studies of preemptive analgesia in which a preincisional 
intervention is compared with the very same intervention initiated after incision, but before the end of surgery (treatment combination 
2 versus 3 in Figure 9.1). This design was used in the study by Katz et al.54(11) in which the two groups of patients undergoing lateral 
thoracotomy received epidural fentanyl or saline before, and epidural saline or fentanyl 15 minutes after, incision, respectively. Pain 
ratings in the group that received preincisional epidural fentanyl were significantly lower six hours after surgery and morphine 
consumption was significantly lower between 12 and 24 hours after surgery. 
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Figure 9.3 Experimental design and expected postoperative outcome for studies of preemptive analgesia in which a preincision 
intervention is compared with the very same intervention initiated after surgery (treatment combination 2 versus 4 in Figure 9.1). 
According to the classic view of preemptive analgesia, the expected outcome is based on the assumption that the intraoperative 
nociceptive barrage contributes to a greater extent to postoperative pain and analgesic use than do postoperative noxious inputs. This 
design was used in the study by Dierking et alS5 who compared a lidocaine inguinal field block administered 15 minutes before hernia 
repair with the same treatment administered immediately after surgery. Significant differences in pain or analgesic use were not found 
between the pre- and postsurgical treatment groups raising the possibility that a preventive effect went undetected due to lack of a 
control group (see Figures 9.4 and 9.5). 
design does not allow for other equally plausible alter-
natives. For certain surgical procedures, central sensitiza-
tion may be induced to an equal extent by incision 
and intraoperative trauma on the one hand (i.e. in the 
postsurgical treatment group) and postoperative inflam-
matory inputs and/or ectopia on the other (i.e. in the 
preoperative treatment group) which would lead to non-
significant intergroup differences in pain and analgesic 
consumption. 57, 58 
Two-group studies that fail to find significant differ-
ences in postoperative pain or analgesic consumption 
between groups treated before or after incision or surgery 
are inherently flawed because of the absence of an 
appropriate control group (e.g. treatment combination 1 
or 8, or both in Figure 9.1). The negative results may 
point to the relative efficacy in reducing central sensiti-
zation of postincisional or postsurgical blockade and not 
the inefficacy of preoperative blockade (for examples, see 
Figures 9.4 and 9.5 depicting studies Katz et al.57,58 and 
Gordon et al.59 ). Recent studiesS7,58 have highlighted the 
critical importance of a standard treatment control group. 
Inclusion of such as group has made it possible to 
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Figure 9.4 Experimental design (treatment combination 1 versus 2 versus 3 in Figure 9.1) used by Katz et al. s7. 58[11] to address the 
design flaw inherent in two-group studies of preemptive analgesia (Figure 9.2). In females undergoing abdominal gynecological surgery 
by laparotomy, preincisional (G1) but not postincisional (G2) administration of epidural lidocaine and fentanyl was associated with a 
significantly lower rate of morphine use, lower cumulative morphine consumption, and reduced hyperalgesia compared with a sham 
epidural condition (G3),58[11] Three-week follow up showed that pain disability ratings were significantly lower in the two groups that 
received the epidural when compared with the standard treatment groupS7[11] Results highlight the importance of including a standard 
treatment control group to avoid the problems of interpretation that arise when two-group studies of preemptive analgesia (pre- versus 
postincision) fail to find the anticipated effects. 
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Figure 9.5 Experimental design used by Gordon et 01. 59[11] to assess the relative effects on late postoperative pain of blocking, or not 
blocking, noxious intraoperative and/or postoperative inputs (treatment combination 1 versus 2 versus 4 versus 6 in Figure 9.1). Patients 
were randomly assigned in a double-blinded manner to receive a local anesthetic (lidocaine or bupivacaine) or saline before and/or at the 
end of third molar extraction surgery. Preventive analgesia is demonstrated by the finding that 48 hours after surgery, pain intensity was 
significantly less in the groups whose postoperative pain was blocked by bupivacaine (G2, G4) compared with preoperative administration 
of lidocaine (G1) or the saline control group (G3), The results suggest that for third molar extraction surgery, the peripheral nociceptive 
barrage in the hours following surgery contributes to a greater extent to central sensitization and late postoperative pain than does the 
intraoperative nociceptive barrage since local anesthetic blockade after surgery was more efficacious than preoperative blockade. 
demonstrate reductions in acute postoperative pain and 
morphine consllmption,58 as well as pain disability three 
weeks after that would otherwise have gone 
undetected using tbe two-group design. 
The near exclusive fOCliS in the literature on the narrow 
view of preemptive analgesia has had the unintended 
effect of diverting attention away from other clinically 
significant findings because they do not conform to what 
has become the accepted definition of preemptive 
analgesia.4 For example, certain studies60• 6 ! evaluate the 
effects of altering the timing of administration of various 
analgesic agents in a manner similar to that described 
above for the classic two-group preemptive analgesia 
design, except that the intent is not to compare pre-
versus postincisional or postsurgical treatments. Rather, 
as illustrated in Figure 9.6, both groups may receive the 
target intervention preoperatively, differing only in how 
long before surgery the treatment is given.6 ! Such a study 
evaluates the effect on postoperative pain and analgesic 
consumption of blocking versus not blocking pre-
operative pain in the context of intraoperative and post-
operative epidural blockade and demonstrates that relief 
of preoperative pain is associated with reduced analgesic 
use 48 hours after surgery.61 Finally, other reports59 have 
demonstrated that for certain types of surgery, blocking 
the peripheral nociceptive barrage in the hours after 
surgery decreases pain at later time periods, whereas 
blocking the intraoperative nociceptive barrage does not 
(Figure 9.5). Taken together, these shortcomings of the 
classic view of preemptive analgesia, and its associated 
design, indicate that an expanded conceptualization and 
explication of the rationale for, and effects of, blockade 
across the three perioperative phases is required to move 
us beyond the current state of confusion that pervades the 
field of preemptive analgesia. 
PREVENTIVE ANALGESIA 
A more encompassing approach, termed preventive 
analgesia, has evolved with the aim of minimizing 
sensitization induced by noxious perioperative stimuli 
including those arising preoperatively, intraoperatively, 
Preoperative 
condition 
Pre-incision 
condition 
and postoperatively. A preventive analgesic effect is 
demonstrated when postoperative pain andlor analgesic 
consumption is reduced relative to another treatment, 
and/or a placebo treatment or no treatment as long as the 
effect is observed at a point in time that exceeds the 
clinical duration of action of the target agent (e.g. treat-
ment combination 1 versus 2, 1 versus 5, or 1 versus 8 in 
Figure 9.1). The requirement that the reduced pain and/or 
analgesic consumption be observed after the duration of 
action of the target agent ensures that the preventive effect 
is not simply an analgesic effect. As we have previously 
pointed out,4, 5, 56[1J such a design does not provide 
information about the factors underlying the effect or the 
time frame within which the effect occurred due the 
absence of a post-treatment condition (see Figures 9.7 
and 9.8 for illustrations of studies by Tverskoy et al.62 [IIl 
and Reuben et al.,63[IIl respectively, who used these 
designs). 
Demonstration of a preventive effect does not require 
that an intervention be initiated before surgery; the tim-
ing of treatment may be during the procedure (e.g. 
treatment combination 1 versus 3 in Figure 9.1) or eVen 
after surgery (e.g. treatment combination 1 versus 4 in 
Figure 9.1). For example, a preventive effect is present if 
postoperative administration of a target analgesic agent, 
but not a placebo, results in reduced postoperative pain or 
analgesic consumption after the effects of the target agent 
have worn off (for a case in point see Figure 9.9 depicting 
the study by Reuben et al.64 [II]). In fact, any two or more 
treatment combinations in Figure 9.1 can produce pre-
ventive effects. The focus of preventive analgesia is not on 
the relative timing of analgesic or anesthetic interventions, 
but on attenuating the impact of noxious perioperative 
stimuli that induce peripheral and central sensitization 
and that increase postoperative pain intensity and 
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Figure 9.6 Two-group experimental design used by Klasen et 0161 [11] comparing the administration of an active agent at different 
times before surgery in order to examine the effect on postoperative pain and analgesic consumption of blocking versus not blocking 
preoperative pain in the context of intraoperative and postoperative epidural blockade (treatment combination 8 versus 8 in Figure 9.1). 
This study61[11] demonstrates that relief of preoperative pain by epidural ropivacaine for at least 12 hours before surgery followed by 
intraoperative epidural ropivacaine (G1) is associated with reduced patient-controlled epidural analgesia (PCEA) ropivacaine consumption 
48 hours after surgery compared with preoperative epidural saline and intraoperative epidural ropivacaine (G2). 
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Figure 9.7 Experimental design comparing two different preoperative interventions with a no treatment control condition (treatment 
combination 1 versus 2 versus 2 in Figure 9.1), This design was used by Tverskoy et 0/.62[1ll in the very first prospective study of 
preventive analgesia, Patients undergoing inguinal herniorraphy were randomly assigned to receive one of three types of anesthesia: 
general plus preoperative local anesthetic infiltration (G1). spinal (G2), or general (G3). While anesthesia (infiltration or spinal) 
significantly decreased movement-associated pain intensity at 24 hours after surgery compared with the control group, the infiltration 
group reported the least pain overall. This pattern of pain scores was still apparent ten days after surgery in response to mechanical 
pressure applied to the wound, 
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Figure 9.8 Experimental design comparing a preoperative plus postsurgical intervention with a placebo control condition (treatment 
combination 1 versus 8 in Figure 9.1), Preventive analgesia is demonstrated if the preoperative plus postsurgical intervention condition 
shows less pain and/or analgesic consumption than the placebo control group beyond the clinical duration of action of the target 
analgesic. This deSign was used by Reuben et al.63 [11] who randomly assigned females to receive venlafaxine (75 mg daily) or placebo 
(daily) for a two-week period beginning the night before radical mastectomy. Six-month follow up showed that the incidence of chest 
wall pain, arm pain, and axilla pain was significantly lower in the venlafaxine group than the placebo group. 
analgesic requirements, A preventive analgesic effect 
involves demonstrating reduced pain and/or analgesic use 
beyond the clinical duration of action of the target agent. 
RATIONALE FOR PRESENT REVIEW 
Recent evidence-based reviews of randomized, double-
blind studies reported in the literature on preemptive4,47. 
52,65, 66[I] and preventive4, 47. 67[1] analgesia suggest that 
there are clinically significant benefits associated with 
both approaches to postoperative pain prevention, 
although the positive evidence is more abundant for the 
latter than the former. The more equivocal results for 
preemptive analgesia likely reflect the fact that intra-
operative and postoperative noxious inputs contribute to 
central sensitization, thus diminishing the magnitude of 
the effect when pre- and posttreated groups are com-
pared. The aim of the present review is to critically 
evaluate the recent literature on preemptive and pre-
ventive analgesia and to compare and contrast the results 
from both approaches. 
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Figure 9.9 Experimental design comparing two postincision analgesic interventions with a placebo or no treatment control condition 
(treatment combination 1 versus 4 versus 4 in Figure 9.1). Preventive analgesia is demonstrated if the postincision condition shows less 
pain and/or analgesic: consumption than the control group beyond the clinical duration of action of the target analgesic. This design 
was used by Reuben et al.64 [11] who showed that morphine, but not saline, administered into the iliac bone graft harvest site (HS) 
during cervical spinal fusion surgery reduced short-term pain and analgesic consumption, as well as the incidence of chronic donor site 
pain one year after surgery when compared with a group that received intramuscular morphine and a placebo control group that 
received saline. The study illustrates that preventive analgesia can be achieved even when the analgesic intervention is started after 
incision and bone graft harvest (i.e. in the context of an unchecked peripheral nociceptive injury barrage during surgery). 
SEARCH STRATEGIES AND CRITERIA FOR 
INCLUDING STUDIES 
A PubMed database search was conducted from January 
2001 to September 2006. Search strategies were limited to 
English language and studies using human subjects. Each 
of the following key words was searched: pre-emptive 
analgesia, preemptive analgesia, preempts, pre-operative, 
preoperative, postoperative, pre-incision, preincision, 
post-incision, postincision. A second search was con-
ducted using the same time period and the same limits. 
The terms searched were as follows: (gabapentin or 
NSAIDs or (NSAIDs and preoperative) or (NSAlDs and 
postoperative) or NMDA or (NMDA and preoperative) or 
(NMDA and postoperative) or opioids or (opioid and 
preemptive) or (opioid and preoperative) or (opioid and 
postoperative) or local anesthetics or (local anesthetics 
and preemptive) or (local anesthetics and preoperative) 
or (local anesthetics and postoperative)). 
The above search strategies yielded 333 publications 
which were retrieved and reviewed by both authors. All 
clinical trials were evaluated according to the following 
inclusion criteria for entry into the present review: (1) 
randomized; double-blind assessments of pain and 
analgesic use; (3) report of pain using a reliable and valid 
measure; report of analgesic consumption; (5) absence 
of design flaws, methodological problems, or confounds 
that render interpretation of the results ambiguous. Trials 
that fit the above definition of preventive analgesia were 
considered not relevant and were not considered further if 
they did not report measures of postoperative pain and 
analgesic consumption at a point in time that equaled or 
exceeded 5.5 half-lives of the target agent. This criterion 
was included to ensure that the observed effects are not 
simply analgesic effects. We excluded clinical trials that 
involved third molar extraction and those evaluating 
neuraxial opioids due to controversy over half-life data.68 
Table 9.1 lists the half-lives of the drugs used for the 
present chapter. 
Of the 333 publications, 61 clinical trials were identi-
fied that met the above inclusion and exclusion criteria. 
Table 9.2 contains the 34 studies that were excluded from 
review, showing which one or more of the five inclusion 
criteria were not met. The 61 studies were evaluated and 
scored for methodological quality by both authors using 
the Jadad quality index scale. The scale uses a six point 
(0-5) rating system (in which lower quality articles 
receive lower scores) to assess the likelihood of bias in 
pain research reports based on descriptions of randomi-
zation, blinding, and withdrawals. A data extraction 
process was performed on the articles that met inclusion 
criteria. The following items were collected: publication 
details, sample surgical procedure, nature and timing 
of interventions, target agent, route and dose of target 
agent, nature and time after surgery of preemptive or 
preventive effect. 
Table 9.3 shows the various experimental designs 
(depicted in Figure 9.1) and the frequency with which 
Table 9.1 Half-lives of drugs and source of half-live information used in studies of preventive analgesia. 
Drug/source of information 
local anesthetics 
Bupivacaine69 
Lidocaine69 
Mexiletine70 
Ropivacaine69 
Nonsteroidal anti-inflammatory drugs 
Celecoxib 71 
Flurbiprofen 71 
Ibu profen 71 
Ketoprofe n 71 
Ketorolac71 
Piroxicam 71 
Potassiu m diclofenac69 
Rofecoxib 
Tenoxicam69 
NMDA receptor antagonists 
Dextromethorphan 69 
Ketamine70 
Magnesium 70 
Opioids 
Fentanyl70 
Morphine7o 
Pethidine 70 
Remifentanil70 
Sufentanil70 
Other analgesic and nonanalgesic agents 
Paracetamol (acetaminophen) 70 
Clonidine70 
Dexmedetomidine70 
Gabapentin69 
Nitroglycerin70 
Promethazi ne 70 
Venlafaxi ne 70 
Half-life 
Lv.: 3.5 hours 
epidural: 2-5 hours 
PNB: 4-12 hours 
Infilt: 2-8 hours 
Lv.: 1.6 hours 
epidural: 1-3 hours 
PNB: 1-3 hours 
Infilt: 1-4 hours 
10-12 hours 
Lv.: 1.9 hours 
epidural: 2-6 hours 
PN B: 5-8 hours 
I nfilt: 2-6 hours 
6-12 hours 
6 hours 
2-4 hours 
2 hours 
4-6 hours 
45-50 hours 
1.5 hours 
17 hours 
60 hours 
1.2-3.9 hours 
2.5-3 hours 
8 hours 
3-4 hours 
4 hours 
3 hours 
8-20 minutes 
3-4 hours 
4 hours 
6-20 hours 
2 hours 
6-7 hours 
1-4 minutes 
9-16 hours 
11 hours 
Criterion value ofS.Shalf-lives 
Lv.: 19.25 hours 
epidural: 27.5 hours 
PNB: 66 hours 
Infilt: 44 hours 
Lv.: 8.8 hours 
epidural: 16.5 hours 
PNB: 16.5 hours 
Infilt: 22 hours 
66 hours 
i.v.: 10.45 hours 
epidural: 33 hours 
PNB: 44 hours 
Infilt: 33 hours 
66 hours 
33 hours 
22 hours 
11 hours 
33 hours 
11.4 days 
8.25 hours 
93.5 hours 
13.75 days 
21.45 hours 
16.5 hours 
44 hours 
22 hours 
22 hours 
16.5 hours 
1.8 hours 
22 hours 
22 hours 
4.6 days 
11 hours 
38.5 hours 
1.5 hours 
3.6 days 
60.5 hours 
Lm., intramuscular; Infilt, infiltration; i.v., intravenous; NMDA, N-methyl-D-aspartate; p.o., per os; PNB, peripheral nerve 
block. 
Also shown is the criterion value of 5.5 half lives used to determine inclusion of studies evaluating preventive analgesia 
(i.e. with a no treatment or placebo control group). Only studies that reported a measure of pain and analgesic 
consumption beyond the criterion value were eligible for inclusion in the present review as assessing preventive effects. 
This requirement was not in place for studies of preemptive analgesia [Le. in which treatment control groups received 
the same intervention but at different times). 
Table 9.2 Studies excluded from review in the present chapter 
for failing to meet one or more of the following criteria: rando-
mized (R), double-blind assessments (DB), report of pain using a 
reliable and valid measure (Pl, report of analgesic: consumption (AJ. 
and absence of methodological problem, design flaw, or confound 
that renders interpretation of the results ambiguous (MFl. 
Author 
Lee et al.73 
Senturk et af. 31 
Yegin et at.14 
Senagore et a/75 
Cerfolio et a/,76 
Korhonen et a/.77 
Karakaya et al. 78 
Lee-Elliott et aes 
Batra et af,80 
Sundarathiti et al81 
Abramov et a/82 
Herbland et 0/. 83 
Seet et alB4 
Yukawa et alB5 
Busch et ai, B6 
Subramaniam et al.87 
Papaziogas et 01,88 
Weinbroum et 01.89 
Weinbroum et 01,90 
Weinbroum91 
Weinbroum et al.92 
O'Flaherty and Lin93 
Hayes et a/,94 
Boleal et alBS 
Ca rney et alBE 
Mallory f't al.97 
Wnek et al98 
Nikanne f't a/. 99 
Canbay et alwo 
Louizos et al. 101 
Wordliczek et al.102 
Machida et 01.103 
Bellissant et al. 104 
De Pietri et 01.105 
Yellr Drug class 
2001 LA 
2002 LA 
2003 LA 
2003 LA 
2003 LA 
2004 LA 
2004 LA 
2004 LA 
2005 LA 
2005 LA 
2005 
2006 
2006 
2005 
2006 
2001 
2001 
2001 
2002 
2002 
2003 
2003 
2004 
2005 
2001 
2002 
2004 
2005 
2006 
2006 
2002 
2004 
2004 
2006 
LA 
LA 
LA 
Multimodal 
Multimodal 
NMDA antagonist 
NMDA antagonist 
NMDA antagonist 
NMDA antagonist 
NMDA antagonist 
NMDA antagonist 
NMDA antagonist 
NMDA antagonist 
NMDA antagonist 
NSAID 
NSAID 
NSAID 
NSAID 
NSAID 
NSAID 
Opioid 
Opioid 
Opioid 
Opioid 
Criterion 
not.met 
R 
DB 
DB 
DB 
A 
DB 
DB 
DB 
DB 
DB 
MF 
A 
DB 
DB 
DB 
P 
A 
R 
MF 
R 
MF 
A,P 
A 
DB 
R 
R, DB 
DB 
A 
A 
DB 
DB 
DB 
P 
DB 
LA, local anesthetic; NSAID, nonsteroidal anti-inflammatory drug; NMDA, 
N-meth yi -D-as pa rtate. 
they were used across the 61 studies for each class of 
analgesic and anesthetic agent. For each design, the table 
also shows whether the effect being evaluated is pre-
emptive or preventive as defined above. The enonnous 
variability in timing of treatment is evident from the fact 
that 23 different designs have been implemented. Table 9.4 
summarizes the outcomes of the studies reviewed below 
according to the target agent administered, including 
gabapentin, local anesthetics, opioids, nonsteroidal anti-
inflammatory drugs (NSAID), N-methyl-D-aspartate 
(NMDA) receptor antagonists, multimodal therapy (three 
or more target agents), and other, traditionally, non-
analgesic/anesthetic agents. Positive studies are defined as 
those that report a significant preemptive or preventive 
effect (i.e. reduced pain or analgesic consumption, or 
both). Negative studies are defined as those for which the 
treatment and control groups did not differ significantly in 
terms of pain or analgesic consumption. Also listed in the 
table is the frequency of studies reporting effects opposite 
to that predicted (e.g. in a study of preemptive analgesia, 
the postsurgical treatment group demonstrated 
nificantly less pain and/or used fewer analgesics than the 
preincisional treatment group). 
LITERATURE REVIEW 
Gabapentin 
Gabapentin is a structural analogue of y-aminobutyric 
acid (GABA) and was introduced into clinical practice as 
an anticonvulsant drug. Its main binding site is believed to 
be the alpha-2-delta subunit of voltage-dependent calcium 
channels, but its full mechanism of action is not well 
understood. J06 Other postulated mechanisms of action 
have been proposed, such as selectively activating GABAB 
receptors, selectively enhancing the NMDA current at 
GABAergic interneurons, or blocking Cl-amino-3-hydroxy-
5-methylisoxazole-4-propionic acid (AMPA) receptor-
mediated transmission in the spinal cord. 106 More 
recently, gabapentin has been shown to increase tonic 
inhibitory conductance in mammalian hippocampal 
neurons. 107 Thus, a combination of peripheral and central 
effects likely mediate the clinical effects of this drug. 
Gabapentin has been demonstrated to be effective in 
the treatment of neuropathic pain, diabetic neuropathy, 
postherpetic neuralgia, and reflex sympathetic dystro-
phy. JOS Gabapentin has been described as an anti-
hyperalgesic drug that selectively affects the nociceptive 
process involving central sensitization. l08 In volunteers, 
oral gabapentin profoundly suppressed established cuta-
neous hyperalgesia after heat-capsaicin sensitization and 
was able to prevent the development of cutaneous sensi-
tization. 109 
Over the past six years, there have been 20 clinical trials 
examining the effects of gabapentin on postoperative 
pain.1l0, 111, 112, l!3, 114, 115, 116. 117, 118, J 19,120.121.122, 123,124, 125. 
126, 127,128.129 All but two of these studiesl!4, 123 have found 
that gabapentin significantly reduces pain, as well as 
the amount of postoperative opioid required (16-67 
percent). 
Table 9.5 shows the six studies that were found to have 
examined designs assessing preemptive and preventive 
analgesic effects of perioperative gabapentin. The Jadad 
et al.72 quality index scores of the six articles ranged from 
four to five with a mean ± S.D. of 4.3 ± 0.52. Of the six 
Table 9.3 Variety and frequency of experimental designs used to evaluate the preemptive and/or preventive effects of different classes of 
analgesic agents. 
Design Treatment Preemptive Gabapeotin ·~9~<!J········· OpiQi~rNsAIDs NMDA ' Multimodal Other Total 
............. 
number combinations in and/or . anC:$tI1~ics antagonists •. No. of 
Figure 9.1 preventive studies 
1,2 PV 5 3 12 
2 1,2,3 PE and PV 2 4 
3 1,2,3,5 PE and PV 1 
4 1,2,4 PE and PV 3 5 
5 1,2,5 PE and PV 
6 1,3,3,3 PE and PV 
7 1, 3, 5 PE and PV 
8 1,4 PV 2 
9 1,4,4 PV 1 
10 1,4,6 PE and PV 
11 1, 5 PV 1 3 4 
12 1,8 PV 2 2 2 8 
13 1,8,8 PV 
14 1,8,8,8 PV 
15 2,2 PE 
16 2,3 PE 2 2 
17 2, 4 PE 2 2 2 2 8 
18 2, 4, 5 PE and PV 
19 2,4,6 PE and PV 
20 3,4 PE 1 
21 4, 4, 4 PV 1 
22 4, 8 PE 2 2 
23 8, 8 PE 
Total 6 13 5 14 14 5 4 61 
NSAIDs, nonsteroidal anti-inflammatory drugs; NMDA, N-methyl-o-aspartate; PE, preemptive; PV, preventive. 
Each design (column 1) is defined in terms of specific treatment combinations (column 2) depicted in Figure 9.1. Each design is also described as 
evaluating preemptive and/or preventive effects (column 3). 
Table 9.4 Summary of studies according to target agent administered showing total number of studies, number (oto) with positive and 
negative preemptive and preventive effects. 
Agent(s) No. studies Prevel) tive effects Opposite Total No. 
Posithle(Ofo) Negative (Ofo) 'effects (0(0) effel:ts , (Ofo) 
Gabapentin 6 0(0) 1 (16.7) 4 (66.6) 1 (16.7) 0(0) 6 (100) 
Local anesthetics 13 3 (20) 3 (20) 6 (40) 1 (6.7) 2 (13.3) 15 (100) 
Opioids 5 3 (60) 1 (20) 0(0) 1 (20) 0(0) 5 (100) 
NSAIDs 14 7 (43.8) 3 (18.8) 4 (25) 2 (12.4) o (O) 16 (100) 
NMDA antagonists 14 2 (11.8) 1 (5.9) 9 (53) 4 (23.4) 1 (5.9) 17 (100) 
Multimodal 5 1 (16.7) 1 (16.7) 2 (33.3) 2 (33.3) 0(0) 6 (100) 
Other 4 1 (25) 0(0) 3 (75) 0(42.9) 0(0) 4 (100) 
Total" 61 17b (24.6) 10 (14.5) 2St (40.6) 11 (15.9) 3 (4.4) 69 (100) 
Also shown is the number (010) of studies reporting effects opposite to that predicted and the total number of effects. The total number of effects exceeds the number 
of studies because some studies were designed to evaluate both preemptive and preventive effects. See text for definition of preemptive and preventive effects. 
a p; 0.02 for z-test comparison of proportion of total positive preemptive plus preventive effects (0.64) versus proportion of total negative preemptive plus 
preventive effects (0.31). 
b p; O. 36 for z-test comparison of proportion of total positive preemptive effects (17/27; 0.63) versus proportion of total negative preemptive effects (lOt 
27;0.37). 
c p; 0.03 for z-test comparison of proportion of total positive preventive effects (28/39 = 0.72) versus proportion of total negative preventive effects (11/ 
39; 0.28). 
NSAIDs, nonsteroidal anti-inflammatory drugs; NMDA, N-methyl-D-aspartate. 
Table 9.5 Studies examininq the preemptive and preventive effects of perioperative gabapentin. 
Author Surgical procedure Treatment Group: first Route and dose Timing of first Timingof second Quality Nature and time after surgery 
(No. patients) combinations intervention drugl intervention intervention score of preventive and lor 
(Figure 9.' ) second intervention preemptive analgesic effects 
drug 
Menigaux Arthroscopic anterior 1,2 6A plus: p.o. 1200 mg 1-2 h preop NA 4 "Preventive effect yes 
et al. 117 cruciate ligament G1' GABA/na VAS pain: no inter-group 
differences beyond t1/2 = 5.5 
lives 
62: PLA/na Cumulative Lv. PCA morphine 
consumption: G1 <G2 at 48 h 
"First/maximal and 
flexion on post-op day 2: 
G1<G2 
Fassoulaki Abdominal 1, 8 GA plus: 400 mg p.o. 18 h preoperation Continues on 4 "Preventive effect - yes 
et al. 114 hysterectomy (60) G 1: GABA/GABA and every 6 h same schedule One month follow up: ·Pain 
(3 doses) until until 5 days incidence: G1 <G2 
G2: PLA/PLA surgery postoperatively Analgesic use: G1 G2 
Turan Abdominal 1, 8, 8, 8 GA plus: ROF p.o. 50 mg 1 h preoperatively 9 a.m. on the first 5 Preventive effect no 
et al. 129 hysterectomy G1: PLA/PLA GABA p.o. 1.2 9 and second 3-month follow up 
(100) G2: ROF+PLA/ postoperative No intergroup differences in pain 
ROF+ PLA days incidence 
G3: GABA+PLA/ 
GABA+PLA 
G4: 
ROF+GABA 
(Continued over) 
Turan Elective lower limb 1,8 
et 01.127 surgery (40) 
et 01.122 
Fassoulaki 
et 01.113 
donor 1.2,3 
Breast cancer surgery 1, 8, 8 
(75) 
GA plus: 
G1: PtA/PLA 
G2: GABA/GABA 
GA 
G1: 
G2: 
G3: PtA/PtA 
GA plus: 
G 1: MEXIL +PLA/ 
MEXll+PtA 
G2: 
GABA+PLA 
G3: 
PLA 
'Nature and time after surgery of preventive analgesic effects. 
1.2 9 p.o. 
GABA p.o. 600 mg 
GABA 600 mg NG 
MEXIL p.o. 200 mg 
TID 
postoperatively 
GABA p.o. 400 mg TID 
postoperatively 
1 h preoperatively 9 a.m. on the first 
and second 
postoperative 
days 
2 
One dosage the 
evening 
before the 
after 
TID for 10 days 
postoperatively 
5 
4 
4 
• Preventive effect - yes 
VRS-R pain: no inter-group 
differences beyond t§ 5.5 
lives 
G2<G1 at 
PARACET usage: G2 < G 1 
Preventive effect - na 
effect - no 
VAS-R: G1 =G2<G3 at 0, 6,12, 
18, and 24h 
Fentanyl use: G 1 < G3 G2 
a Preventive effect - yes 
'3 month follow up chronic 
characteristics: 
G1 =G2<G3 
use: no 
differences 
G, group; GA, general anesthesia; GABA, gabapentin; Lv., intravenous; MEXIL, mexiletine; na, not applicable; NG, nasogastric; PARACET, paracetamol; PCEA, patient-controlled epidural analgesia; PLA, placebo; p.o., per 
as; ROF, rofecoxib; TID, three times daily; VAS-RIM, visual analog scale pain score at restlon movement. 
studies identified, only one fits the classification of a 
. d· 122 h h fi d· 113 114 117 127 preemptive eSlgn. T e ot er ve stu les . , , , 
129 provided data to assess the preventive effects of 
gabapentin beyond the 5.5 half-lives (40 hours) after the 
final administration of the drug. Four of the five studies 
(80 percent) demonstrated impressive preventive effects 
in favor of the gabapentin treated versus placebo control 
group. Perioperative gabapentin administration was 
associated with a significant decrease in postoperative 
opioid consumption,117, a reduction in the inci-
dence of pain at the surgical incision site one month after 
surgery,114[IIJ and a reduction in neuropathic pain three 
months after surgery. 1I3 [II] 
Only one studyl22[IIJ evaluated the preemptive effects 
of gabapentin. Pandey and colleagues l22 [IIJ compared 
preincisional versus immediate postincisional adminis-
tration of gabapentin (600 mg) with a placebo control 
group (treatment combination 1 versus 2 versus 3 in 
Figure 9.1) in open donor nephrectomy patients. The 
results showed that patients in the pre- and postincision 
groups had significantly lower pain and used less fentanyl 
than those in the control group. The absence of a pre-
emptive effect likely is due to the fact that the gabapentin 
was given too earl y after incision in the postincisional 
group. 
The optimal dose of gabapentin for perioperative use 
has not been established, but a recent meta-analysis130 
and systematic review131 that doses between 600 
and 1200 mg have robust opioid-sparing and pain-
relieving effects in the acute postoperative period. The 
preventive effects of gabapentin are quite promising. For 
example, the study by Menigaux et al.ll7 demonstrated 
the effectiveness of gabapentin in decreasing anxiety 
scores and improving early functional recovery after 
anterior cruciate ligament knee surgery. Patients treated 
with one preoperative dose of 1200 mg of gabapentin had 
significantly improved range of motion on active and 
passive knee flexion on postoperative day two in com-
parison to placebo-treated l-'a'Ll"J.H~. 
Although only six studies have examined the pre-
emptive or preventive effects of gabapentin in the peri-
operative period, the perioperative pain-reducing and 
opioid-sparing effects of gabapentin beyond the acute 
perioperative period are quite promising; including the 
possibility that pain incidence may be reduced up to three 
months after surgery. Future studies are needed to clarify 
the optimal dosing and timing of gabapentin in the 
perioperative period. 
Local anesthetics 
Table 9.6 describes the 13 studies that were found to have 
examined designs assessing preemptive and preventive 
analgesic effects using local anesthetic agents. Surgical 
procedures included major gynecologic surgery by lapar-
otomy,S7,58, 132 major abdominal surgery, 133 thoracic 
surgery,134 median sternotomy,135 laparoscopic surgery,I36 
laparoscopic cholecystecomy, 137 appendectomy,138 total hip 
replacement,61 total knee arthroplasty,139 knee arthro-
scopy, 140,141 and craniotomy.142 Routes of administration 
included epidural58, 61,132,134 intravenous (i.v.), 133,135 sub-
cutaneous (S.C.),136, 137, 138, 142 intra-articular (i.a.),140,141 
and a combination of intramuscular (i.m.), s.c., and i.a.139 
Although only tw058, J34 of the 13 studies were 
designed to assess the effects of co-administration of a 
local anesthetic and an opioid, all but two studies61 , 139 
administered opioids at induction of general anesthesia 
and/or during surgery, so that it is not possible to attri-
bute effects solely to the target local anesthetic agent. 
As shown in Table 9.4, of the 15 effects that were tested 
(in the 13 trials), 37.5 percent (3/8) showed significant 
preemptive effects, approximately 87 percent (6/7) 
showed significant preventive effects, and 25 percent (2/8) 
showed preemptive effects that were opposite in direction 
to the hypothesized effect, in that the postincisional group 
showed reduced pain compared with the preincisional 
group. Of note is the study by Katz et al.,58 [Ill who found 
that short-term beneficial effects of preventive epidural 
analgesia (whether administered before or after incision) 
translated into less pain disability at three weeks but not 
six months after surgery.57 
Opioid analgesics 
The effect of preinjury treatment with opioids on pre-
venting spinal postinjury hyperexcitability is well docu-
mented. 143 Early studies by Woolf and Wall 144 showed 
that the amount of morphine required to prevent the 
development of this spinal hyperexcitability was ten-fold 
less than the amount required to reverse it after it was well 
established. More recent animal studies have also shown 
that the application of mu-opiate receptor agonists pre-
empt development of hyperalgesia and allodynia follow-
inflammation, surgery, or nerve injury.145, 146 
However, the efficacy of opioid pretreatment in 
decreasing central sensitization and thus reducing pain is 
somewhat more equivocal in human trials. Several studies 
have demonstrated that preoperative opioid administra-
tion reduces postoperative pain and consumption of 
analgesics when compared with postoperative adminis-
tration 147 or a placebo control,148 the latter effect occur-
ring beyond the clinical duration of action of the target 
opioid. However, others have failed to demonstrate pre-
emptive effects. 149 A growing body of evidence over the 
past ten years has also suggested that under certain con-
ditions opioids may induce some forms of central sensi-
tization and facilitate development of hyperalgesia. ISO 
Despite the mixed picture of opioids with respect to their 
hyperalgesic and analgesic actions, they continue to have a 
major role in perioperative pain management. 
Table 9.7 shows the five studies that were found 
to have examined designs assessing preemptive and 
Table 9.6 Studies examining the preemptive and preventive effects of local anesthetics (± opioid) as the target treatment. 
Author Procedure (No. Treatment Group: First Route and dose Timing of first Timing of second Quality Nature and time after 
patients) combinations intervention drug{ intervention intervention score surgery dfpteventive 
(Figure 9.1 ) second and/or preemptive 
intervention drug analgesic effects 
Katz et 01.58 and Major gynecologic 1, 2, 3 GA plus: Epidural 12 mL LID 2 After placement of 40 min post- S a Preventive effect - yes 
Katz and surgery by G1: LlD+FENT/ Epidural FENT 4 ~g/kg epidural catheter incision bpreemptive effect - yes 
(141 ) SAL before incision 
G2: SAL/ VAS-R: No inter group 
LlD+ FENT differences, 'VAS-M: 
61 <63 at 24h 
G3: SAL/SAL Hourly PCA Morphine: 
bGl <62 G3 for day 
1; •. bGl G2<G3for 
day 2 
Von Frey pain threshold 
at 24h: "Gl >G3 at 
24h 
3-week follow-up: Pain 
Disability Index: 
"61 G2<G3 No 
differences analgesic 
use 
6 month follow-uo: No 
diffe 
incidence, 
disability or 
use 
Neustein et 01. 134 Thoracic surgery (32) 4, 8 GA Epidural 20 mg BUP After induction but Postoperative 3 bpreemptive effect - no 
G 1: BUP+FENT/ and 100 ~lg FENT pre-incision infusion started VAS pain: 
BUP+FENT/ followed by an followed by intra in PACU (Gl, 
BUP+FENT intra-operative op infusions G2) 
G2: SAL/SAL! infusion of BUP 0.1 61 <G2 at 0-6 h (exact 
BUP+FENT and FENT 10 ~g/ml time of effect not 
at 6 ml per h known) 
reduced to 2 mL PCEA: no differences in 
per h in PACU median epidural 
infusion rate 
[Continued over) 
Table 9.6 Studies examininq the preemptive and preventive effects of local anesthetics (± opioid) as the target treatment (continued). 
Author Procedure (No. Treatment Group: First Route. and dose Timing of first Timing of second Quality Nature and time after 
patients) combinations intervention drug} intervention intervention score surgery of preventive 
(Figure 9.1) second and/or preemptive 
intervention drug analgesic effects 
Vendittoli et 01.139 Total knee arthroplasty 1,8 Spinal BUP plus: Lm. tissues) i.m. before prosthesis s.c. before wou nd 4 a Preventive effect - yes 
(42) 275mg implantation closure and La. 
G1: Nad/Nad/Nad s.c. 125 mg on first day ·VAS pain at 2 
G2<G1 
G2: ROP/ROP/ROP i.a. 150 mg Analgesic use: G2<G1 
up to 48 h 
Active assisted knee 
flexion day 1-5: No 
inter group 
differences 
Koppert et 01.133 Major abdominal 1, 8 GA Lv. LID bolus 1.5 mg/kg Bolus after intubation; na 5 a Preventive effect - yes 
surgery (40) G 1: SAL/na followed by i.v. LID infusion started VRS-R: No differences 
infusion 1.5 mg/kg/ 30 min before post-op at any time 
G2: LlD/na h surgical incision VRS-MAUC: aG2<G1 
and maintained 24-48 hand 48-72 h 
until 60 min post PCA morphine: 
op aG2<G1 at 36-48, 
48-60 and 60-72 h 
Cumulative PCA 
morphine: G2<G1 
Lohsiriwat Appendectomy (123) 1,5 GA plus: s.c. 10 mL 0.5 5 min before incision na 3 a Preventive effect - yes 
et 0/.138 G1: SALIna and just after aVAS-M: G2<G1 at 48h 
G2: BUP/na incision of skin and 
s.c. tissue 
G2<G1 at 48h 
Lam et 01.136 Laparoscopy (144) 1,2, 3 GA plus: S.c. 10 mL 1 LID Before incision Before closure 5 bpreemptive effect -
oppo 
G1: LID/SAL a Preventive effect - yes 
G2: SAL/UD Pain levels: 
G3: SAL/SAL "G2<G3 at 24h 
bG2<Gl at 24h 
No differences in 
consumption prior to 
discharge 
(Continued over) 
Burmeister 
et 01. 132 
et 01.142 
Lou izos et 01.137 
et 01.141 
Tuncer et 01.140 
Klasen et 01.61 
White et 01.135 
Craniotomy (30) 
Laparoscopic 
cholecystectomy 
(108) 
4,8 
1, 4 
1,2,3,5 
Knee (40) 2,4 
rthrn<rnn,r knee 2. 4 
surgery 
Total hip replat'ement 8e, 8 
(42) 
Median sternotomy 1,4,4 
GA 
G1 : 
G2: 
GA 
G1: na/ROP 
G2: na/PLA 
GA pius: 
G1: SAL/SAL 
G2: L-BUP/SAL 
G3: SAL/L-BUP 
G4: 
GA 
G1: 
G2: PLA/BUP+EPI 
Lv. sedation 
G1: BUP/SAL 
G2: SAl/BUP 
Lv. sedation plus: 
G1: ROP/ROP 
G2: SAL/ROP 
GA 
G1: 
G2: 0.25 
G3: na/BUP 0.5 
bolus 10 mL 
0.375 followed by 
infusion 
s.c. 20 mL 0.75 
Bolus before 
induction; infusion 
until end of skin 
closure 
na 
S.c. 20 mL 0.25 L-BUP Before incision 
i.p. 20 mL 0.25 L-BUP 
La. 15 mL 0.5 15 min oreooeration 
i.a. BUP 20 ml 0.25 30 min before incision 
Epidural: ROP 0.2 at Continuously starting 
5 mL/h 12 h preoperation 
up until arrival in 
OR 
Lv. infusion 4 na 
At end of skin 4 
closure; 
tinu 
until 24 hours 
postoperatively 
At skin closure 4 
Before skin closure 4 
After surgery 5 
Immediately after 3 
skin closure 
Pre-incision 1 ROP 4 
to achieve 
sensory 
blockade to T8 
and 
surgery 
from 3 
end of surgery 
until 48 h post-
operation 
effect - no 
Preventive effects - no 
Preventive effect - na 
b Preemptive effect -
shoulder 
G3<G2 
Pr .... mntill .. effect - no 
b Preem ptive effect - yes 
bVAS-R/M: G1 <G2 at 1, 
2, 4 and 6 h 
bpreemptive effect - yes 
VAS pain: No intergroup 
differences post-
operation 
bTotal PCEA ROP 
G1 <G2 
at 48 h: 
"Preventive effect - yes 
"VAS Pain: 03<G1 at 
72h 
Mean i.v. PCA morphine 
usage: G3 < G 1 at 
72h 
"Hospital stay: G3<G1 
AUC, area under the curve; FENT, fentanyl; G, group; GA, general anesthesia; i.a., intaarticular; i.p., intraperitoneal; i.v., intravenous; L-BUP, levo-bupivacaine; LID, lidocaine; na, not applicable; Nad, nothing administered; 
OR, operating room; PACU, postanesthetic care unit; PCEA, patient controlled epidural analgesia; PLA, placebo; ROP, fopivacaine; SAL, saline; s.c., subcutaneous. 
"Nature and time after surgery of preventive analgesic effects. 
bNature and time after surgery of preemptive analgesic effects. 
<The classification of this study as evaluating preemptive analgesia is not entirely accurate. While it does evaluate the effect of altering the timing of administration, it does not do so before versus after incision. 
Table 9.7 Studies examining the preemptive and preventive effects opioids as the target treatment. 
Author Procedure (No. of Treatment Group: first Route and dose Timing of first Timing of second Quality Nature and time after 
patients) combinations intervention drugl intervention intervention Score surgery of preventive 
(Figure 9.H second and/or preemptive 
intervention drug analgesic effects 
Reuben et 01.155 Arthroscopic knee 2,4 IV sedation plus IA MORPH i.a. 3 mg 30 min preoperation At end of surgery 3 Preemptive - yes 
surgery (40) 
G 1: MORPH/Nad VAS-RIM: G1 G2 at 1, 
2 and 24h 
G2: Nad/MORPH 24 h analgesic 
consumption: 
G1 <G2 
McCarty et 01.153 Anterior cruciate 1,2 GA plus post- S mg i.a. After induction but na 3 Preventive effect no 
ligament operation pre-incision 
reconstruction (62) femoral nerve 
block: 
G1 : 
G2: 
Mavioglu et 01.152 Total abdominal 3, 4" GA plus: 0.5 i.v.+bolus During closure of In PACU 4 I-'reemptlve yes 
hysterectomy G 1: PETH/Nad doses of 10 mg fascia VAS-R: G1 <G2 at 0,15, 
3D, 60 and 120 min 
G2: Nad/PETH PETH use: G1 <G2 at 
0-15, 15-30, 30-60 
and 60-120min 
(Continued over) 
Munoz et 01. 154 
Akural et 01.151 
Laparoscopic 
cholecystectomy 
(120) 
Abdominal 
hysterectomy 
1,3,3,3" 
2,4 
GA 
G 1: SAL!SAVSAL 
G2: SAL/SAL! 
MORPH 
G3: 
SAL 
G4: MORPH/5AL/ 
SAL 
GA plus: 
G 1: SUFENT/SAL 
G2: SAL/SUFENT 
MORPH i.v.150 
50 )1g 
First intervention: Third intervention 4 
> 40 min from end < 20 min from 
of surgery end of surgery 
Second intervention: 
20-40 min from 
end of surgery 
20 min pre-anesthesia 20 min after 
closure of 
3 
Preventive effect - na 
Preemptive effect - no 
Preemptive effect yes 
NRS pain-RIM: no inter 
group differences 
postop to 1 month 
PCEA SUFENT 
G 1 < G2 at 8-16 h 
Touch detection 
threshold AUC for 4 
days: G1 <G2 
Pain threshold AUC for 4 
days: G1 <G2 
Aue, area under the curve; BUP, bupivacaine; G, group; GA, general anesthesia; i.a., inta-articular; i.v., intravenous; min, minutes; MORPH, morphine; na, not applicable; NRS pain RIM. numeric rating scale for pain at 
rest/on movement; Nad, nothing administered; PACU, postanesthetic care unit; PCEA, patient controlled epidural analgesia; PETH, pethidine; PLA, placebo; SAL, saline; SUFENT, sufentanil; VAS-RIM, visual analog scale pain 
score at rest/movement. 
'The classification of this study as evaluating preemptive analgesia is not entirely accurate. While it does evaluate the effect of altering the timing of administration, it does not do so before versus after incision. 
preventive analgesic effects of opioids in the perioperative 
period. IS !' 152,153.154.155 The Jadad et a/.72 quality index 
scores of the five articles ranged from three to four with a 
mean ± S.D. of 3.4 ± 0.55. Routes of administration 
included were i.a. (morphine), Lv. (pethidine [meper-
idine], morphine) and epidural (sufentanil, treatment 
combination 2 versus 4 in Figure 9.1). The relatively few 
studies examining the preventive effects of opioids (i.e, 
five) was due to our exclusion of all trials involving 
neuraxial opioids since there is a lack of a consensus on 
half-life values of opioids delivered by the epidural and 
spinal routes.68 The five trials included in Table 9.7 
studied the effects of opioids in the following four sur-
gical populations: total abdominal hysterectomy,151, 152 
laparoscopic cholecystectomy,154 anterior cruciate liga-
ment repair,153 and arthroscopic meniscectomy.155 
Of the five studies, four used preemptive designs (three 
positivel 51 , 152, 155[II] and one negative I54), while only 
one 153 met the criteria for a preventive trial. Reuben 
et al. (treatment combination 2 versus 4 in 
Figure 9.1) demonstrated that preoperative i.a. injection 
of morphine was superior to postoperative injection in 
decreasing pain scores and morphine consumption follo-
wing arthroscopic knee surgery. Akural et al.l5l[IIl (treat-
ment combination 2 versus 4 in Figure 9.1) demonstrated 
that preoperative epidural sufentanil was superior to 
dural sufentanil administration near the end of surgery. 
Postoperative pain was significantly lower in the pre-
versus postincisional group for up to four days after sur-
gery, lSI [II] The only negative preemptive studi 54 used a 
clinically nonrelevant design (treatment combination 1 
versus 3 versus 3 versus 3 in Figure 9.1) and evaluated the 
effects on postoperative pain and analgesic consumption 
of i.v. morphine administered at three time points during 
laparoscopic cholecystectomy versus a saline control. The 
sole preventive study153 we identified compared the effects 
of preincisional i.a. morphine compared to placebo in 
patients undergoing anterior cruciate ligament recon-
struction. The authors did not find evidence of an effect of 
i.a. morphine on pain or analgesic consumption, but this 
not surprising since all patients received postoperative 
femoral nerve blocks with at least 20 mL of 0.5 percent 
bupivacaine. Thus, the only plausible conclusion is that 
i.a. morphine provides no additional benefit when com-
bined with effective postoperative femoral nerve blocks. 
Opioids continue to have a significant role in peri-
operative pain management despite significant adverse 
effects such as nausea, vomiting, sedation, pruritus, 
constipation, urinary retention, and respiratory depres-
sion. 156 The problem of accurately identifying the half-life 
of neuraxially administered opioids6B essentially limited 
our review of these agents to studies using preemptive 
designs. Longer follow-up times after surgery (e.g. weeks 
or months) would obviate the problem of determining an 
accurate half-life of epidural and spinal opioids. More 
research is needed to clarify the role of opioids in pre-
emptive/preventive analgesia. 
NSAlDs 
The analgesic effects of NSAIDs have been attributed to 
their anti-inflammatory actions in inhibiting the synthesis 
of prostaglandins.ls7 Prostaglandin (PG) synthesis is 
essential for the generation of inflammatory pain and this 
depends not only on prostaglandin production at the site 
of inflammation, but also on the actions of prostaglandins 
synthesized within the central nervous system (CNS). 
Prostaglandins derive from arachidonic acid liberated 
from phospholipids in the cell membrane by the action of 
phospholipase A2 (PLA2) enzymes. ISS Cyclooxygenase 
(COX) catalyzes the first two reactions of the PG pathway. 
The identification of two COX isoforms, COX-l and 
COX-2, led to intense efforts to characterize the relative 
contribution of each isoform to prostaglandin production 
in specific situations. ISS 
Marked increases in PLA2 and COX-2 expression occur 
at the site of pelipheral inflammation. Prostaglandins 
themselves do not produce pain, but sensitize receptors at 
the site of injury to a variety of neurochemicals (e.g. 
bradykinin, serotonin, substance P, calcitonin gene-related 
peptide).1S7 Recent evidence has also demonstrated that 
peripheral inflammation induces a widespread increase in 
COX-2 and prostaglandin synthase expression in neurons 
and nonneuronal cells in the spinal cord. 159 An elevation 
of COX-2 also occurs at many levels in the brain, mainly 
in the endothelial cells of the brain vasculature. 
Samad et al. 158 proposed two signaling systems through 
which peripheral injury and its inflammatory sequelae are 
relayed to the CNS. The first is the traditional, electrically 
mediated transmission system, in which neural activity in 
sensitized nerve fibers innervating inflamed tissue signals 
the location of injury, as well as the onset, duration, and 
nature of any stimuli applied to this tissue. The second is a 
nonneuronally mediated system in which a humoral sig-
naling molecule (or molecules), originating in inflamed 
tissue, acts via the bloodstream to produce a widespread 
induction of COX-2 in the CNS. Following peripheral 
injury, there is an immediate (within minutes) and delayed 
(within hours) spinal release of the former produced 
by COX-l and/or COX-2, and the latter by COX_2. 157• 160 
This suggests that acute postoperative pain may not be as 
sensitive to COX-2 inhibitors as the pain experienced some 
time later.158 The net effect of both the peripheral and 
central actions of NSAIDs would be to prevent or 
attenuate development of a hyperexcitable state in spinal 
cord dorsal hom neurons. In terms of the patient's 
experience of pain after surgery, this would translate into 
less intense pain and a reduced requirement for post-
operative analgesics. Based on data from basic science and 
clinical research, NSAIDs may preempt different compo-
nents of postoperative pain (e.g. central and peripheral 
sensitization) by more than one mechanism, and pro-
longed blockade of inflammation by NSAIDs throughout 
the perioperative period and beyond has demonstrated a 
decrease in the development of chronic pain. 
Table 9.8 shows the 14 studies that were found to have 
examined the preemptive and preventive effects of NSAID 
administration in the perioperative period. The Jadad et 
al.72 quality index scores of the 14 articles ranged from 
two to five with a mean ± S.D. of 3.8 ± 0.89. Routes of 
administration include oral, rectal, and i.v. A variety of 
NSAIDs were used which differ in the extent of their anti-
inflammatory activity, analgesic effects, antipyretic 
actions, and pharmacokinetics. 
Of the 14 studies identified, ten fit the classification of 
a preemptive 60,161,162,163,164,166,168,169,170,172 
Two of the 14 studies also examined effects beyond 5.5 
half-lives of the drug, one demonstrating a posi-
tive/70 [II] and the other, a negative169 preventive effect. 
The other four studies used designs that assessed the 
• f'C f NSAID . . 165.167,171,173 preventive elects 0 mterventIOns. 
Of the six studies that reported preventive effects, four 
(66.7 percent) reported positive findings, and of these, 
both Buvanendran et az.!67[II] and Rueben et al. 161 [IIJ 
demonstrated significant long-term benefits at one month 
and one year after surgery, respectively. Buvanendran et 
al. 167 found that a two-week perioperative regimen of 
rofecoxib in total knee arthroplasty patients improved 
range of motion in comparison to controls at a one 
month follow up. Reuben et al. 161 [II] administered cel-
ecoxib or placebo, to patients scheduled for spinal fusion, 
for five days beginning one hour before surgery. The 
incidence of chronic donor-site pain was significantly 
lower in the celecoxib group (four of 40 patients, or 10 
percent) compared with the placebo group (12 of 40 
patients, or 30 percent) at one year after surgery. Cel-
ecoxib-treated had a 74 percent lower risk for 
developing chronic pain than the placebo-treated patients 
at one year. 
COX-2 selective inhibitors were originally marketed as 
safer alternatives to nonselective nonsteroidal anti-
inflammatory Recent studies demonstrating a link 
d d· d I b'd' 174,175 to long-term use an car lac an rena mor I lty 
have culminated in the withdrawal of rofecoxib and val-
decoxib from the marketplace. Although the evidence 
suggests a fairly consistent cardiovascular risk rate with 
rofecoxib, the evidence for cardiovascular risk with cel-
ecoxib is equivocal. 176 It is important to note that the 
long-term cardiovascular risk associated with COX-2 
inhibitors, which resulted in the withdrawal of rofecoxib, 
was demonstrated in patients taking the medication for 
more than two years. The analgesic and opioid-sparing 
effects associated with COX-2 inhibition were demon-
strated with short-term use (eight days at most).161. 
In summary, the results of the present review 
that perioperative NSAID use is associated with clinically 
significant preemptive and preventive effects with a suc-
cess rate approaching 70 percent. Long-term benefits at 
one month and one year after surgery were associated 
with COX-2-selective NSAlD (rofecoxib/celecoxib) 
administration. Given their long half-life (Table 9.1), the 
anti-inflammatory properties of these agents continued to 
be active for some time after surgery, even when admi-
. d . I . d 161 Thi mstere as a smg e preoperative ose. s may con-
tribute to a longstanding block of the inflammatory 
response and a reduction in peripheral sensitization. 
Prolonged central effects of NSAIDs may also contribute 
to the prevention of central sensitization significantly 
attenuating the development of hyperexcitability in spinal 
cord dorsal horn neurons. Further research is required to 
confirm and extend the initial promising short- and long-
term benefits of preventive COX-2 inhibition. 
NMDA receptor antagonists 
A variety of agents that have an antagonistic action at the 
NMDA receptor are clinically available, including aman-
tadine, dextromethorphan, ketamine, ketobemidone, 
memantine, and methadone. At the present time, pre-
ventive or preemptive analgesic effects have been investi-
gated using ketamine or dextromethorphan, but not the 
other NMDA antagonists. Although ketamine hydro-
chloride177 and dextromethorphan178 act on a variety of 
receptor systems, their NMDA channel-blocking properties 
quickly became the focus of intense research once this 
receptor-ion channel complex was discovered to play a 
critical role in the induction and maintenance of central 
... d hI' 1 . 179 180 Th . h . senSItIzatIOn an pat 0 oglca pam.' e mec al1lsm 
proposed to underlie the reduced opioid consumption and 
pain in studies of preemptive analgesia is the prevention 
(or reversal) of NMDA-mediated sensitization of spinal 
cord dorsal horn neurons.4 , 51 The NMDA channel blockers 
dextromethorphan and ketamine are of particular interest, 
therefore, in testing the hypothesis that perioperative 
administration will lead to reduced pain and analgesic 
consumption using preventive and preemptive designs. 
Table 9.9 shows the 14 studies that were found to have 
examined designs assessing preemptive and preventive 
analgesic effects ofketamine (n 10) or dextromethorphan 
(n=4). The Jadad et al.72 quality index scores of the 14 
articles ranged from three to four with a mean ± S.D. of 
4.4 ± 0.64. The most frequent designs have compared 
preoperative administration of dextromethorphan or 
ketamine with a placebo or an active agent (i.e. evaluation 
of preventive effects). The next most commonly used 
designs compare preoperative administration of dex-
tromethorphan or ketamine with the same agent admi-
nistered either intraoperatively, postoperatively, or both 
preoperatively and postoperatively (Table 9.3). 
KETAMINE 
The preemptive and preventive use of ketamine has been 
studied on a variety of surgical procedures including lower 
• 193 I kn h I 182,187 abdommal surgery, tota ee art rop asty, gyne-
. 183 d 1 184 185 cologlcallaparotomy an aparoscopy, gastrectomy, 
. 186 ill 194 major ear, nose, and throat surgery, tons ectomy, 
Table 9.8 Studies examininq the preemptive and preventive effects of NSAlDs. 
Author Procedure (No. of Treatment Group: first Route and dose Timing of first Timing of second Quality Nature and time after 
combinations intervention drugl intervention intervention Score surgery of preventive 
(Figure 9.1) second and/or preemptive 
intervention drug analgesic effects 
Reuben etal. 161 knee 1,2,4 Sedation Lv. IA 50mg p.o. 1 h preoperation 15 min after 4 Preventive effect na 
surgery (60) BUP plus: surgery 
61: ROF/PLA Preemptive effect yes 
62: PLA/ROF Verbal Analogue Pain at 
rest: 61 G2<63 at 
2+24h 
G3: PLA/PLA Verbal Analogue Pain at 
movement: 
61 <G2<G3 at 1, 
2+24h 
24 h consumption of 
PARACET/OXYCOD: 
G1<G2 G3 
Kokki and Pediatric 1,4,6 GA Bolus Lv. 0.5 mg/kg Bolus 5 min after PACU bolus 4 Preventive effect - na 
tonsillectomy G" KETOP /SAL! Infusion i.v. 3 mg/kg/h induction but followed by Preemotive effect - no 
(109) KETOP before surgery 24 h infusion 
G2: SAl/~ 
KETOP 
G3: SAL/SAL/SAL 
Gramke et al.163 Laparoscopic bilateral 2,4 GA plus: Sublingual 40 mg 2 h preoperation 10min 3 effect - yes 
inguinal hernia G 1: PIROXI/PLA postoperation VAS-R: G1 <G2 at 6 and 
(52) 20h 
G2: PLA/PIROXI Cumulative Lv. PCA 
tramadol: 
Norman et 01.164 Ankle fracture surgery 2, 3 GA 30 mg i.v. After induction, while Immediately after 5 Preemptive effect yes 
G1: KETOR/PLA the leq was beinq tourniquet VAS-R: G1 <G2 at 2 and 
inflation 4h 
G2: PLA/KETOR « 15 min after PCA morphine: No inter 
intervention 1) group differences 
(Continued over) 
Reuben et 0/. 165 Spinal fusion (80) 1,8 GA plus infiltration 400 mg preoperation 1 h preoperation 12h 3 Preventive effect - yes 
of proposed p.o., 200 BID 
incision sites postoperation until 5th day 
with BUP plus: 
G 1 : CELECOX/ One year follow up: 
CELECOX 
G2: PLA/PLA Chronic donor site 
Gl <G2 
G 1 patients had a 74 
lower risk for chronic 
pain than G2 
Boccara et a/,166 Laparoscopic 2, 4 GA plus: KETOP 100 mg Lv. Before induction After surgery 4 Preventive effect - na 
cholecystectomy G 1: KETOP/PLA PARACEf 2 g Lv. Preemptive effect - yes 
(104) G2: PLA/KETOP VAS Pain: 
G 1 < G2 = G3 = G4 at 
0,1,2,3, lOand 12h 
63: PARACEf/PLA No of pain-free patients 
during 24 h: 
G1 <G2 G3 64 
G4: PLA/PARACEf No. of patients with 
severe pain (VAS 
G1 <G2 G3 
Cumulative nalbuphine 
at 24 h: 
G1 =G2 
Buvanendran et Total knee 1, 8 Sedation (Lv.) plus 50 mg per day p.o. 24h and 1-2h Once daily for 5 5 Preventive effect - yes 
al. 167 arthroplasty (70) spinal BUP preoperation days then 
preop plus 25 mg/day for 8 
post- more days 
op plus: 
G1: ROF/ROF One-month 
G2: PLA/PLA Range of motion of 
affected knee: 
G1 >G2 
[Continued over) 

Salonen et 01.172 on,ilif'rtom\l (106) 1,2,4 
Lim et 01.173 Cesarean section (48) 1,4 
Q'Hanlon et 01.60 2, 2· 
GA 
G1: 
G2: SAL/KETOP 
G3: SAUSAL 
0.5 Lv. bolus 
anesthesia 100 mg p.r. 
plus: 
G 1: na/DICLOF 
G2: na/na 
GA plus wound 20 mg i.v. 
infiltration with 
BUP at end of 
procedure 
G 1: TENOX/Nad 
G2: NadTENOX 
After induction but 
na 
30 min 
In the PACU 
After Cesarean 
section 
At induction of 
anesthesia 
5 
3 
4 
Preventive effect - na 
Preemptive effect - no 
Preventive effect yes 
VAS-M: no inter group 
differences post-
operation 
PCEA consumption: 
G1<G2 at 12-18h 
Total PCEA 
G1 <G2 at 24h 
effect - yes 
VAS Gl <G2 at 30, 
60, 120 and 240 min 
No. of patients requiring 
additional 
G1<G2 
Demerol and D1CLOF 
usage for first 4 h: 
61<G2 
BID, twice daily; BUP, bupivacaine; CELECOX. celecoxib; DICLOF, diclofenac; G, group; GA, general anesthesia; lA, intaarticular; IBU, ibuprofen; IV, intravenous; KETOP, ketoprofen; KETOR, ketorolac; min, minutes; na, not 
applicable; Nad, nothing administered; OXYCOD, oxycodone; PACU, postanesthetic care unit; PARACET, paracetamol (acetaminophen); PCA, patient controlled analgesia; PCEA, patient controlled epidural analgesia; PIROXI, 
piroxicam; PLA, placebo; p.o., per as; p.r., per rectum; ROF, rofecoxib; SAL. saline; TENOX, tenoxicam; TID, three times daily; VAS-C, visual analog scale pain score when coughing; VAS-RIM, visual analog scale pain score at 
rest/movement. 
aThe classification of this study as evaluating preemptive analgesia is not entirely accurate. While it does evaluate the effect of altering the timing of administration, it does not do so before versus after incision. 
Table 9.9 Studies examining the preemptive and preventive effects of the NMDA receptor antaaonists ketamine and 
Author Procedure (No. of Treatment Group: First Route and dose Timing of first Timing of Quality Nature and time after 
patients) Combinations intervention drugl intervention second score surgery of preventive 
(Fig ure 9.1) second intervention intervention and/or preemptive 
drug analgesic effects 
Helmy and Upper-abdominal 1, 2, 3 GA plus: 120 mg i.m. 30 min before 30 min before 4 Preventive effect na 
Bali 's, suraerv [60) G1: DEXTRO/SAL incision end of Preemptive - yes 
G2: SAL/DEXTRO surgery VAS-RIM: G1 <G2 G3 
at 6 h 
G3: SAL/SAL Total i.v. PCA 
(meperidine) 
consumptiol 
G1 <G2 =G3 
Himmelseher Total knee 1, 2 Lumbar epidural ROP Epidural 0.25 mg/kg 10 min before na 5 Preventive effect yes 
et 01. 182 arthroplasty (37) plus: incision 
G1: SAL/na VAS-RIM: G2<G1 at 
24 and 48 h 
G2: KETAM/na Cumulative PCEA ROP: 
et 01.'83 Gynecologic 2,4,5 GA plus: Bolus i.v. 0.5 mg/kg Before induction of Third intervention 4 Preventive effect - yes 
laparotomy G 1: KETAM/SALI Infusion Lv. 6OO1l9/kg/ anesthesia after wound Preemptive effect 
surgery (45) SAL h (G2) followed by closure (G3) opposite 
G2: KETAM/KETAM /SAL infusion VAS-R: G2=G3<G1 at 
0-24h 
G3: SAL/SALI KETAM VAS-C: G2 G3<G1 at 
24h 
i.v. PCA 
G1 G2=G3 at 
0-24h 
Kwok et 01. 184 Gynecologic 1, 2, 4 GA plus: 0.15 mg/kg i.v. Immediately before After wound 5 Preventive effect - no 
laparoscopic G 1: KETAM/SAL induction of closure Preemptive effect - yes 
surgery (135) G2: SAL/KETAM anesthesia VAS pain: G1 <G2~G3 
at 0 to 6 
63: SAL/SAL Cumulative Lm. 
morphine: 
G1 <G2= G3 
(Continued over) 
Xie et 01.185 Gastrectomy (45) 1, 2 GA plus PCEA post G1: 0.5 i.v. 15 min before na 4 Preventive effect yes 
op plus: incision 
G,' KETAM/na G2: Epidural 0.5 mg/kg VAS-R: 
G2: KETAM/na Gl<G3at24h 
G3: SAUna G2 < G3 at 24, 36 and 
48 h 
G2< G1 at 24,36 and 
48 h 
Cumulative PCEA 
aL48h: 
G2<G1 <G3 
Ganne et 01.186 Major ear, nose, and 1,5 GA plus: Bolus Lv. 0.15 Bolus before na 5 Preventive effect no 
throat surgery G1: KETAM/na followed by i.v. induction 
G2: SAlina infusion 2 ~lg/kg followed by 
continuous 
infusion during 
anesthesia 
Adam et 01.187 Total knee 1.8 GA olus: Bolus i.v. 0.05 mL/kg Just after induction Maintained at 5 Preventive effect yes 
followed by of anesthesia second level 
(40) intraoperation from initial 
G1: KETAM/KETAM I Infusion i.v. 3119/kg/ bolus until Maximal active knee 
KETAM min then reduced emergence flexion at days 6 
to 1.5 ~lg/kg/min from and 7: G1 >G2 
G2: SAL/SAL/SAL for 48 h anesthesia, Maximal active knee 
then reduced flexion at 6 weeks 
until 48 h and 3 months: 
postoperation G1 =G2 
Katz et 01.188 Radical 1, 3, 5 GA plus: Bolus i.v. 0.2 mg/kg Bolus 10 min before Bolus 70 min after 5 Preventive effect - no 
prostatectomy G1: KETAM/SAL followed by i.v. incision followed incision Preemptive effect - no 
(143) G2: SAl/KETAM infusion by infusion for followed by VAS-RIM: no inter 
0.0025 maika/min 70 min infusion until group differences at 
the end of any time 
G3: SAl/SAL surgery Von Frey thresholds: no 
inter group 
differences at any 
time 
Cumulative i.v. PCA 
10rphine 
at 
72 h: G1 G2=G3 
(but G 1 vs G2 and 
G1 vs G3; p= 
(Continued over) 
Table 9.9 Studies examining the and 
Author Procedure (No. of 
patients) 
Ozyalcin et al. 189 Thoracotomy 
Treatment 
Combinations 
(Figure 9.1) 
1,2 
effects of the NMDA receptor ketamine and dextromethorphan (continued). 
Group: First 
intervention drug/ 
second intervention 
drug 
GA plus: 
G1: KETAM+SAL/ 
na 
G2: SAL+KETAM/ 
na 
G3: SAL +SAL/na 
Route and dose 
(G 1) 1 mg/kg i.m. 
Epidural (G2) 1 mg/kg 
Timing<of first 
intervention 
Timing of 
second 
intervention 
15 min preoperation na 
Quality Nature and time after 
score surgery ofpteventive 
and/or preemptive 
analgesic effects 
5 
Hourly PCA 
consumption: 
G 1 < G2 '" G3 from 
48 h to 72 h 
2 week follow-up: VAS-
R: G1 G2",G3 
Preventive effect - yes 
At 48 h: pinprick 
Pressure 
G1 62<G3 
Brush allodynia: 
G2<61 <63 
Cumulative PCEA 
at 48 h: 
82<81 <63 
Cumulative PCEA 
morphine BUP: 
62<G1 ",83 
15 day follow up 
Brush allodynia: 
62<81 <63 
Pinprick 
82<G1 83 
Pressure hyperalgesia: 
62<G3 
30 
(Con tinued over) 
Yeh et al.190 
Wu et a/.191 
Weinbroum 
et al. 192 
Kafali et a/.193 
Van Elstraete 
et 0/. 194 
Colonic surgery 
Laparoscopic 
cholecystectomy 
(100) 
1,5 
1, 2, 5 
Lower body surgery 1, 2 
Lower abdominal 
surgery 
Tonsillectomy (40) 
1, 2 
1, 5 
GA plus thoracic 
epidural plus: 
G1: 
G2: PLA/LiD 
G3: DEXTRO/LiD 
GA 
G1: PLA+PLA/na 
G2: 
G3: 
LID plus: 
G1' PLA/na 
G2: DEXTRO/na 
G3: DEXTRO/na 
GA plus: 
G1: SALIna 
G2: KETAM/na 
GA 
G1: KETAM/KETAM 
G2: SAL/SAL 
na 
DEXTRO Lm. 20 mg 
HID 
10 
DEXTRO i.m. 40 mg 
LID i.v. 3 until 
end of surgery 
DEXTRO p.o. 60 mg 
DEXTRO p.o. 90 mg 
(G3) 
150 Lv. 
0.5 mg/kg i.v. bolus 
followed by Lv. 
infusion 2 Ilg/kg/ 
min 
30min 
30 min preincision 
90 min 
Before incision 
At induction of 
anesthesia before 
incision 
Intraoperatively 
until end of 
surgery 
na 
na 
na 
Infusion 
continued 
until end of 
surgery 
3 
4 
4 
4 
5 
Pin-prick 
G2<G1 <G3 
Pressure hyperalgesia 
No 
differences 
Preventive effect yes 
VAS-C: G 1 G2 > G3 at 
24h 
Cum PCEA volume at 
48 hand 72 h: 
G1 >G2>G3 
Preventive effect yes 
VAS-C: 
G4<G2<G1 =G3 
at24 
Cumulative i.m. 
pethidine at 48 h: 
G4<G3=G2<G1 
Preventive effect - yes 
3-day 
VASPain:G2 G3<G1 
use: 
82 G3<G1 
Preventive effect yes 
VAS pain: G2<G1 at 
48 h 
Cumulative i.v. PCA 
to 48 h: 
G2<G1 
i.v. PCA morphine: 
G2<G1 at 24-48h 
Preventive effect - no 
BUP. bupivacaine; DEXTRO, dextromethorphan; G, group; GA, general anesthesia; i.m., intramuscular; i.v .. intravenous; KETAM. ketamine; LID, lidocaine; Na, not applicable; PCA. patient controlled analgesia; PCEA. patient 
controlled epidural analgesia; PLA. placebo; ROP. ropivacaine; SAL, saline; VAS-C, visual analog scale pain score when coughing; VAS-R/M, visual analog scale pain score at rest/movement. 
radical prostatectomy,188 and thoracotomy,I89 There is 
usually no rationale for the patient population stu-
died, in spite of the fact that important differences clearly 
exist among the various surgical procedures that may have 
a bearing on the outcome of the results (e.g. duration of 
procedure relative to that of the target agent, ex1:ent (deep 
versus superficial) and nature (nerve, muscle, viscera) of 
tissue damage and inflammation). 
Ketamine has been administered by via the i.m.,189 
i.v.,J83, 184, 185, 186,187, 188,193, 194 and epidural182, 185, 189 
routes. Two studies compared the route of administra-
tion, including 1.0 mg/kg ketamine i.m. or epidurallyl89 
and 0.5 mg/kg ketamine Lv. or epidurally.185 In both 
studies,185,189[II] preventive effects were observed for 
epidural ketamine compared with the other route. 
Intravenous ketamine has been administered as a sin-
gle bolus dose/ 84, 185,193 or as a bolus dose followed by a 
continuous infusion l83 , 186, 187, 188, 194 for the duration of 
the surgical procedure. Intravenous bolus doses of keta-
mine have ranged from 0.15 to 0.5 mg/kg with infusions 
ranging from 2-10 f.lg/kg/minute, 
The three studies of epidural ketamine l82, 185, 189:II] 
administered a single, preoperative bolus dose 
(0.25-1.0mg/kg) without infusion. All three showed sig-
nificant preventive 48 hours after surgery, pain 
intensity and postoperative analgesic consumption were 
significantly lower in the ketamine-treated patients com-
pared with the placebo control condition,182, 185, 189[IIl In 
one study,189[II] patients were followed up 15 and 30 days 
after surgery. At both follow-up assessments, brush-evoked 
allodynia and hyperalgesia were still significantly 
less pronounced in the epidural ketamine group compared 
with the Lm. ketamine and saline control groups. The 
pattern of intergroup differences for pressure hyperalgesia 
at the wound was the same for the IS-day follow up, but the 
differences were no significant 30 days after surgery. 
The surgical procedures were performed under general 
anesthesia in all but one of the studies, the exception 
being a positive study of patients undergoing 
total knee arthroplasty with epidural ropivacaine. 182[II] 
Of the ten studies evaluating ketamine, significant 
preventive effects were observed in seven studies,182, 183, 
184,185,187,189,193 [IT] One study183 showed a preemptive 
effect that was opposite to what had been predicted in 
that the group receiving i.v. ketamine after wound closure 
reported significantly lower pain scores at rest and after 
coughing up to 24 hours after surgery compared with the 
preincisional group. As noted above, these results may 
point to the relative greater efficacy in reducing central 
sensitization of postsurgical i.v. ketamine versus pre-
operative blockade, 
DEXTROMETHORPHAN 
Surgical procedures for the four studies using dex-
tromethorphan include upper abdominal surgery, I 81 
colonic surgery,190 laparoscopic cholecystectomy,191 and 
lower body surgery.192 For all studies, dextromtthorphan 
was administered by the i.m. route as a single bolus dose 
ranging between 20 and 120 mg, either before surgery,89, 
190,191 or before versus during surgery. lSI Intramuscular 
dextromethorphan resulted in a preventive effect in 
three89, 190, 191 [II] of the four studies; pain intensity was 
significantly lower between 24 hours 190,191[II] and three 
days89[II] after a single bolus dose of i.m. dex-
tromethorphan. The one study181 that did not find a 
preventive effect did, however, show a short-term pre-
emptive effect in that total patient-controlled analgesia 
(PCA) opioid consumption, as well as pain at rest and 
after movement six hours after surgery, were significantly 
lower in the group that received dextromethorphan 30 
minutes before surgery versus 30 minutes before the end 
of surgery. 
Taken the results of the studies that have 
examined administration of ketamine or dex-
tromethorphan have proved quite successful in that 
approximately 65 percent (11117) of the effects reported 
supported the efficacy of preemptive or preventive 
analgesia. As shown in Table 9.3, almost 69 percent (9/13) 
of the effects evaluating only preventive analgesia show 
that preoperative ketamine or dextromethorphan 
administration results in significantly lower pain intensity 
andlor reduced analgesic requirements after the duration 
of action of the NMDA antagonists have worn off (i.e. 
after more than 5.5 half-lives). These results are very 
similar to those reported by McCartney et al.67 [Il in a 
recent qualitative review of the preventive analgesia lit-
erature from 1966 to 2003. They found that among the 
clinically available NMDA receptor antagonists, dex-
tromethorphan (67 percent (8/12) of studies) and keta-
mine (58 percent (14/24) of studies) showed the greatest 
number of significant preemptive or preventive effects. 
Their data show that 16 of the 30 studies (53 percent) 
evaluating preventive analgesia only (i,e, excluding pre-
emptive showed evidence of a reduction in 
pain, analgesic consumption, or both beyond the clinical 
duration of action of the drug concerned. The similarity 
in outcome between the present review and that of 
McCartney et a1.67 [!] is unlikely to be due to the two-year 
(2001-2003) overlap in the literature reported since, of 
the 3667 [1] and 24 (present review) studies covered, only 
threel81 , 182, 192 were common to both reviews. 
The preponderance of positive studies of ketamine and 
dextromethorphan may be due not only to the ability of 
these agents to block the neural processes underlying 
central sensitization,l77 but in a related vein, to their 
ability to attenuate the development of acute opioid tol-
erance7,195 and reverse opioid-induced facilitation of 
nociceptive processing.196,197 Since opioids were admi-
nistered (as premedication or during surgery) in all but 
three89, 182, 183 of the studies, preoperative administration 
of ketamine or dextromethorphan may also have pre-
vented acute opioid tolerance, opioid-facilitated activation 
of NMDA processes, and opioid-induced hyperalgesia 
relative to the control group leading to a reduction in 
postoperative opioid requirements and postoperative pain 
intensity in the preoperatively treated groups. 
Multimodal analgesic therapy 
The rationale for a preoperative multimodal approach to 
postoperative pain management is to capitalize on the 
combined actions of a variety of classes of analgesic and 
anesthetic agents at different receptor sites in reducing 
peripheral and central sensitization. 198, 199 For the pur-
pose of the present review, we have defined a multimodal 
as involving administration of three or more 
agents in combination. Expectations of the therapeutic 
benefits associated with multimodal regimens include 
improved efficacy, lower doses, and fewer adverse 
effects,200 
Table 9.10 describes the five studies 115, 201, 202, 203,204 
that evaluated the effects of multimodal, combination 
therapy on pain and analgesic consumption using pre-
emptive or preventive designs. The Jadad et al,72 quality 
index scores of the five articles ranged from two to five 
with a mean ± S.D. of 4.2 ± 1,3. Surgical procedures 
include breast cancer surgery, I 15 arthroscopic knee sur-
gery,201,203 nephrectomy,202 and tonsillectomy,204 Of the 
five studies, tw020I ,202 evaluated preemptive effects using 
the classic design (treatment combination 2 versus 4 in 
Figure 9.1) and one2ol [II] showed significant effects in 
favor of the preoperative treatment. Two 115, 204 [II] of the 
remaining three studies 115,203,204 that evaluated preventive 
effects found significant benefits that long outlasted the 
clinical duration of action of the target agents. In a triple-
dummy, placebo-controlled study by Fassoulaki et al.,115 
[II] patients undergoing breast cancer surgery received 
placebo or preoperative gabapentin and trans dermal 
eutectic mixture of local anesthetics (EMLA) followed by 
intraoperative ropivacaine irrigation of the brachial plexus 
and several intercostal spaces, After surgery, patients 
continued to receive placebo or gabapentin every six hours 
for eight days in addition to transdermal EMLA daily for 
three days. Three months (but not six months) after 
surgery, patients in the multimodal treatment group had a 
lower incident of axilla pain, arm pain, chronic pain, and 
analgesic use compared with the placebo control patients. 
Naja et al. 204[II] compared the effects of no treatment with 
a preincisional tonsillar infiltration of a placebo solution 
or a solution containing lidocaine with epinephrine, 
bupivacaine, fentanyL and clonidine in 90 pediatric 
patients undergoing tonsillectomy. Pain at rest, on jaw 
opening, and when eating soft foods were all significantly 
lower in the combination pharmacotherapy group for up 
to at least one week after tonsillectomy, These studies 
provide some of the strongest and most promising evi-
dence of the therapeutic benefits of a (prolonged 115 [II]) 
multimodal analgesic regimen.204[II] 
The study by Rosaeg et al}·OI which compared a com-
bination of local anesthesia, morphine, epinephrine, and 
ketorolac (treatment combination 2 versus 4 in Figure 9.1), 
was designed to look at long-term outcomes as well (Le. 
preventive effects). The authors found that administration 
of their three-component analgesic drug combination 
resulted in lower pain scores in patients that received the 
intervention before versus after surgery. Pain scores and i,v. 
PCA morphine consumption were significantly lower 
during the initial stay in the postanesthesia care unit 
(PACU) (i,e, a positive preemptive effect). However, pain 
scores did not differ significantly between the groups on 
postoperative days one, and seven; thus there was no 
measurable long-term advantage associated with pre-
emptive multimodal drug administration in arthroscopic 
knee surgery (i.e. a negative preventive effect).201 
At first glance, the results describing the multimodal 
studies shown in Table 9.10 seem equivocaL However, it 
is important to note the two studies201 ,203 that reported 
negative preventive effects and the one negative pre-
emptive studlo2 both lacked a placebo control group. 
Thus, the conclusion that these multimodal interventions 
do not exert a clinically relevant benefit may be incorrect. 
Until similar studies are conducted with the appropriate 
control condition(s), these conclusions are premature. 
Other nonanalgesic agents 
Table 9.11 describes the four studies that examined the 
preemptive and/or preventive analgesic effects of other, 
traditionally, nonanalgesic agents, including venlafaxine63 
[II] (a serotonin and norepinephrine reuptake inhibitor 
(SNRI», promethazine205[II] (a histamine I (H]) receptor 
antagonist), nitroglycerine,206[II] and dexmedetomidine207 
[II] (an alpha-2 agonist), All evaluated preventive effects 
with the exception of the study by Chia et al.,205[IIl in 
which both preemptive and preventive effects were exam-
ined (treatment combination 1 versus 2 versus 4 in Figure 
9.1). Thus, of the five effects examined, there were three 
positive preventive effects,63, 206, 207[Il] one negative pre-
ventive effect205 and one positive preemptive effect.205[II] 
The most interesting and promising of these studies, 
conducted by Reuben et al.63 [IIl and depicted in Figure 
9.8, involved administration of venlafaxine 75 mg or 
placebo capsules to women (n = 50 per group) the night 
before surgery and daily for two weeks after radical 
mastectomy. Six month follow-up assessment revealed 
that pain on movement, as well as the incidence of chest 
wall pain, arm pain, axilla pain, chronic pain, and 
analgesic use were all significantly lower in the venlafaxine 
group. Consistent with the results of a rat study/o8 the 
authors suggest that the lower incidence of chronic neu-
ropathic pain six months after surgery may have been 
result of an SNRI-induced reduction of activity in adre-
nergic nociceptive pathways that contribute to central 
sensitization.63 
Table 9.10 Studies examining the preemptive and preventive effects of multi modal analgesic regimens. 
Author Procedure (No. Design Group: First intervention Route and dose Timing of first Timing of second Qual!ty Nature and time after 
of patients) drug/second intervention intervention intervention score surgery of pr~ventive 
drug and/or preemptive 
analgesit effects 
Fassoulaki Breast cancer 1,8 GA plus: GABA p.o. 400 mg GABA - every 6 h 5 Preventive effect - yes 
et 01.115 surgery (50) and until 8th 
every 6 h postoperation 
thereafter 
G1' PLA+PLACRM/ SAL! Irrigation ROP 10 mL EMLA 5 min before EMLA - sternal 3 month follow-up 
PLA+PLACRM surgery area, dose to 
G2: GABAHMLA/ROP/ Transdermal EMLA Intraop ROP the wound, Incidence of: 
GABAHMLA 20 9 irrigation of around the axilla pain: G2<G1 
brachial plexus, incision in the arm pain: G2<G1 
third, fourth, and axilla daily for chronic pain: G2<G1 
fifth intercostal 3 days analgesic use: 62 < G 1 
spaces postoperation 6-month follow up 
no group differences in 
pain or analgesic use 
et 01.,201 Arthroscopic knee 2,4 GA plus: Femoral nerve block 15 min before skin Immediately after 4 Preventive effect - no 
G1' ROP+MORPH+EPI ROP 20 mL 0.25 incision completion of Preemptive effect - yes 
+KETOR/Nad surgery 
G2: Nad/ROP+MORPH ROP La. 20 mL 0.25 VRS Pain: 61 <62 at 0.5, 
+EPI+KETOR 1, 1.5 and 2 h 
MORPH La. 2 mg Cumulative Lv. PCA 
EPI) morphine usage: 
KETOR Lv. 30 mg G1<G2 at 1,2,3,4 
and 5 h 
Holthusen Nephrectomy 2,4 6A plus: 150 fl9/k9 i. v. 15min Immediately after 2 Preemptive effect - no 
et 0/. 202 (3D) 61' MORPH+KETAM MORPH 
surgery 
G2: Nad/MORPH 150 ~Ig/kg KETAM 
+KETAM+CLON 
et ol.LVJ Arthroscopic knee 4,4,4 LID infiltration plus: BUP i.a. 150 mg na At end of surgery 5 Preventive effect - no 
sLlrgery (63) 61: na/BUP ROP i.a. 150 mg 
G2: na/ROP ROP i.a. 150 mg 
G3: na/ROP+MORPH MORPH 4mg 
+KETOR KETOR 30mg 
(Continued over) 
et 01."°4 Pediatric 
tonsillectomy 
1, 2 GA 
G1: LlD+EPI BUP+FENT 
+CLON/na 
G2: 
G3: Nad/na 
Preincisional Before incision na 
infiltration (each 
tonsil 1.5 mL) 
mixture of 
UDHPI, BUP, 
FENT and CLON 
5 Preventive effect - yes 
VAS-R: G1 <G2 G3 at 1, 
2, 3, 4, 7 and 8 days 
VAS-R: G1 <G3 at 5,6,9 
and 10 days 
VAS pain on jaw 
G1 <G2 G3 at 1, 2,3,4, 
7, 8 and 10 
G1 <G3 at 5 and 6 days 
G1<G2 at 9 days 
VAS pain when eating 
soft foods: 
G1 <G2 =G3 at 1,2, 
3, 4, 8 days 
G1 <G2<G3 at 1,2, 
3, 4, 5 and 6 days 
No. of taking 
tramadol: 
G1<G2<G3 at 1,2 and 
3 days 
G1<G2=G3 at 4 and 5 
days 
VAS-R: G1 <G2=G3 at 1, 
2, 3, 4, 7 and 8 
BUP, bupivacaine; CLON, clonidine; EMLA. eutectic mixture of local anesthetics; FENT, fentanyl; G, group; GA. general anesthesia; GABA. gabapentin; i.a .. inta-articular; i.v .. intravenous; KETAM, ketamine; KETOR, ketorolac; 
LID, lidocaine; MORPH. morphine; Nad, nothing administered; PCA. patient controlled analgesia; PLA. placebo; PLACRM, placebo cream; PO. per os; ROP, ropivacaine; VAS-R, visual analog scale pain score at rest; VRS, 
verbal rating scale. 
Table 9.11 Studies examining the preemptive and 
Author Procedure (No. of Treatment 
patients) combinations 
(Figure 9.' ) 
Reuben et 0/.63 Radical mastectomy 1, 2 
with axillary 
node 
dissection (100) 
Chia et 0/.205 Total abdominal 1, 2, 4 
hysterectomy 
(90) 
Unlegenc et OJ.'UI Abdominal surgery 1,2 
(60) 
Sen et 0!?06 Hand surgery 1,2 
effects of other nonanalgesic agents. 
Group: First Route and Dose 
intervention drug! 
second 
intervention drug 
GA plus: 
G1: VENLAF/na 
G2: PLA/na 
GA plus: 
G 1: PROMETH/SAL 
G2: SAL/PROMETH 
G3: SAL/SAL 
GA plus: 
G1: PLA/na 
G2: DEXMED/na 
Sedation i.v. plus: 
G1: 
G2: NITRO+UD/na 
75 mg p.o. 
0.1 mg/kg i.v. 
1 !J.g/kg Lv. for 10 min 
LID Lv. 2 3 mg/kg 
NITRO Lv. 200 ~Lg 
Timing of first 
intervention 
Night before surgery 
and daily for 2 
weeks post-
operatively 
30 min preoperation 
10 min before 
anesthesia 
Immediately 
preoperation 
Timing of second Quality 
intervention score 
na 5 
At end of surgery 4 
na 4 
na 4 
Nature and time after 
surgery of preventive 
and/or preemptiVe 
analgesic effects 
Preventive effect - yes 
At 6 month follow up: 
Pain on movement: 
G1 <G2 
6 month incidence of: 
chest wall pain: G1 <G2 
arm pain: G1 <G2 
axilla G1 <G2 
chronic pain: G1 <G2 
use: G1 <G2 
Preventive effect - na 
effect - yes 
VAS-RIM: No inter group 
differences to 24 h 
Cumulative PCA MORPH: 
G 1 < G2 = G3 at 3, 6, 
2and24h 
Preventive effect - yes 
VAS pain: no inter group 
differences up to 24 h 
Cumulative PCA MORPH: 
G2<G1 at 24h 
PCA morphine 12-24h: 
G2<G1 
Preventive effect - yes 
VAS for tourniquet pain: 
G2<Gl at 30min 
intraoperation 
VAS pain: G2<G1 for 1st 
4 h postoperation 
DICLOF consumption: 
G2<G1 
PARACET 
G2<G1 
DEXMED, dexmedetomidine; DICLOF, diclofenac; G, group; GA, general anesthesia; Lv., intravenous; LID, lidocaine; min, minute; MORPH, morphine; NITRO, nitroglycerin; PARACET, paracetamol (acetaminophen); PCA, 
patient-controlled analgesia; PLA, placebo; PROMETH, promethazine; SAl, saline; VAS-RIM, visual analog scale pain score at rest/on movement; VENLAF, venlafaxine. 
RECOMMENDATIONS FOR FUTURE RESEARCH 
Relationship between preexisting pain and 
timing of analgesic administration 
We know very little about the effects of preexisting, pre-
operative pain on the subsequent development of acute 
and chronic postoperative pain. As it turns out, this 
important issue prompted the very first controlled 
studlo9[III] of "preoperative preemptive analgesia,,38 
which suggested that epidural anesthesia started before 
and continuing for the duration of surgery conferred 
protection from long-term phantom limb pain six months 
after surgery. These promising results were not supported 
by a subsequent randomized trial evaluating the long-term 
effects on phantom limb and stump pain of continuous 
epidural morphine and bupivacaine administered 18 
hours before, during and for about one week after lower 
limb amputation. ls The control group received epidural 
saline before and throughout surgical procedure followed 
by epidural morphine and bupivacaine postoperatively. 
There were no significant differences between the groups 
in pain incidence, intensity, or opioid consumption at any 
time up to 12 months after surgery.IS 
Other more recent studies in nonamputee populations 
have examined the same issue as it pertains to the devel-
opment of acute, as opposed to chronic, postsurgical pain. 
The data suggest that in the presence of presurgical pain, 
preoperative administration of analgesics does not lead to 
the anticipated lessening of postoperative pain or analgesic 
consumption, perhaps because central sensitization has 
already been established. Postoperative pain and analgesic 
consumption were significantly reduced by pre- and intra-
operative epidural morphine, but not saline, for patients 
who did not report presurgical pain.21o[II] However, among 
patients with presurgical pain, pre- and intraoperative 
epidural morphine was no more effective than saline.2l O 
This raises the important issue of what effect blocking 
preoperative pain would have on the intensity of acute 
postoperative pain. A recent study of patients undergoing 
total knee arthroplasty showed that relief of preoperative 
pain by epidural ropivacaine for at least 12 hours before 
surgery, followed by intraoperative epidural ropivacaine, 
reduced patient-controlled epidural analgesia (PCEA) 
ropivacaine consumption 48 hours after surgery compared 
with preoperative epidural saline and intraoperative epi-
dural ropivacaine.61 [II] Based on these interesting and 
controversial findings, future studies should report presence 
(and duration) or absence of presurgical pain. 
Offsetting the competing effects of opioid 
analgesia and opioid-induced tolerance and 
hyperalgesia 
As noted above, recent basic science evidence points 
to the possibility that under certain circumstances, 
preoperative administration of opioid analgesics may 
contribute to the establishment of acute opioid toler-
ance l9S and opioid-induced hyperalgesia. 197, 211 The 
mechanisms underlying the reduced pain and opioid 
consumption brought about by preemptive opioid 
analgesia, and the increased pain and opioid consump-
tion underlying acute opioid tolerance and opioid-
induced hyperalgesia, involve competing processes 
involving the NMDA receptor-ion channel complex. 
These findings have important implications for the COn-
duct of clinical studies evaluating the timing of admin-
istration of opioid analgesics since the main outcome 
measures (pain and opioid consumption) will be directly 
affected by the mechanisms underlying these competing 
neural processes. The net effect of this competition is to 
attenuate (or even reverse) the desired preemptive and 
preventive effects. Coadministration of opioids and low-
dose NMDA antagonists or low-dose opioid antagonists 
has been found to interfere with the development of acute 
"d I 7 212 d "d' d d hI' 213 OplO! to erance ' an OplO! -Ill uce ypera gesla. 
A mechanism-based approach to postoperative pain 
management involving coadministration of these agents 
would be expected to facilitate the preventive and pre-
emptive analgesic effects of opioids in patients under-
going major surgery. 
Recommendations to improve the quality of 
studies 
MEASURES OF PAIN 
The most appropriate pain measurement instruments 
are patient-rated pain scales that have demonstrated 
reliability and validity (e.g. visual analog scale (VAS), 
numeric rating scale, McGill pain questionnaire).214 
Measurement of pain with the patient in a resting posi-
tion is reported by almost all studies. However, the 
measurement of hyperalgesia is important. The simplest 
and most clinically significant test of mechanical hyper-
algesia is to have the patient perform a standardized 
movement after surgery (e.g. sitting up from a lying 
position, inspirational spirometry) and rate the intensity 
of the pain that ensues. More sophisticated measures of 
primary and secondary mechanical and thermal hyper-
algesia include pressure algometry applied either on or 
near the wound dressing2lS or on the side of the body 
contralateral to the incision,216 measurement of thresh-
olds to electrical stimulation,217 temperature,89 and use of 
pinprick, brush,189 and Von Frey filamentsS8,188 at a 
distance from the wound to determine the extent of 
secondary mechanical allodynia and hyperalgesia. Base-
line (preoperative) measures are important as is testing at 
a control site (e.g. a noninjured body part) to rule out a 
generalized effect due to factors such as anxiety, antici-
patory pain, or a response bias. 
MEASURES OF ANALGESIC CONSUMPTION 
The degree of pain a patient experiences in the post-
operative setting is in part a function of postoperative 
analgesic consumption. Use of patient-controlled 
analgesia (either i.v. or epidural) as a modality for post-
operative pain management has dominated the pre-
emptive analgesia literature. This is largely because PCA/ 
PCEA is now the gold standard for postoperative pain 
management at most institutions worldwide. Analgesic 
consumption is usually the primary outcome measure 
since patients self-administer the agent to achieve a 
relatively constant pain level. However, from the point of 
view of demonstrating preemptive analgesia, analgesic 
consumption is not the most ideal measure because the 
main hypothesis deals with pain and hyperalgesia. 
Allowing pain to fluctuate by holding constant the level of 
postoperative analgesics administered would be a more 
direct test of the hypothesis, but this is not always feasible 
or ethical given the evolving standards of pain manage-
ment practice. 
Cumulative analgesic consumption at the end of the 
study is a common measure, but report of a single value 
may not provide specific enough information to pinpoint 
exactly when the effect is observed. This point is not as 
important if a postincision control group is employed. 
However, it is especially relevant in studies that evaluate 
the preventive effect of a preoperative intervention (i.e. 
when comparing it to a placebo) since it is likely that the 
largest difference in PCA consumption between treated 
and untreated groups will occur around the time of peak 
effect of the target agent used preventively. Cumulative 
analgesic consumption at the end of the study may be 
misleading depending on the pattern of consumption 
over time. For example, if a difference in analgesic con-
sumption occurs within the first few hours after surgery, 
when the effects of the analgesics used preventively are 
still active, then this is an analgesic effect. Unless cumu-
lative analgesic consumption is reported at multiple times 
across the study period, an analgesic effect may be mis-
interpreted as a preventive effect or a preventive effect 
may be missed. Likewise, report of a single value for 
cumulative analgesic consumption at the end of the study 
may result in failure to detect the presence of group dif-
ferences at earlier time points. Another approach that 
circumvents this problem is to calculate analgesic con-
sumption within intervals bounded by the times when 
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of specifying an interval within which an opioid-sparing 
effect has occurred. 
SUMMARY AND CONCLUSIONS 
Preoperative pain intensity is a risk factor for develop-
ment of severe acute postoperative pain, as well as long-
term postsurgical pain. Severity of acute postoperative 
pain predicts pain after discharge and also is a risk factor 
for chronic postsurgical pain. These findings have, in part, 
fueled recent preventive and preemptive efforts to reduce 
acute pain intensity and long-term pain problems by 
blocking noxious perioperative inputs. 
Overall, across the classes of agents reviewed, the 
proportion of significant preventive and preemptive 
effects is significantly greater than the proportion of 
negative effects (p 0.02, Table 9.4). The same is true for 
the proportion of positive versus negative preventive 
effects (p = 0.03, Table 9.4). Administration of these 
agents appears to reduce pain, analgesic consumption or 
both at a point in time that exceeds 5.5 half-lives of the 
target agent. Since these extended effects are observed 
after the clinical actions of the agents have worn off, they 
are not analgesic effects. Rather, these effects appear to be 
due to the reduction in perioperative peripheral and 
central sensitization in the treated patients. The greatest 
proportion of positive preventive effects were found for 
the NMDA antagonists ketamine and dextromethorphan 
for which significantly lower pain intensity and/or 
reduced analgesic requirements were found in approxi-
mately 69 percent of the effects tested. In spite of the 
heterogeneity in designs (Figure 9.3) across the 61 clinical 
trials (69 effects) evaluated, it appears that, in general, 
there is a benefit in terms of reduced pain and/or 
analgesic consumption that extends beyond the duration 
of action of the target drug. 
The absence of a difference in the proportion of 
positive preemptive versus negative preemptive effects is 
understandable when one considers that both preinci-
sional and postincisional (or postsurgical) noxious inputs 
contribute to postoperative sensitization.4 [I] The most 
likely conclusion is that for a certain proportion of studies 
of preemptive analgesia, the postincision or postsurgical 
administration condition is as beneficial in reducing 
central sensitization as is the preoperative condition but 
that these benefits go undetected when the comparison is 
made between the two groups. The lack of a control 
group in studies of preemptive analgesia is a serious 
limitation that confounds interpretation of the results and 
has contributed to the premature and erroneous conclu-
sion that there is no clinical benefit to preoperative 
nociceptive blockade. 
The continued use of incomplete designs that consist 
of preincisional and postincisional or postsurgical con-
ditions without a standard treatment group or a complete 
blockade condition will hinder progress in our under-
standing of the benefits of preemptive analgesia. Adhering 
to the narrow definition of preemptive analgesia currently 
accepted by many in the field will perpetuate problems of 
interpretation and will not lead to the evolution and 
progress that is needed to move us beyond the current 
state of confusion. Inclusion of appropriate control con-
ditions is essential if we are to advance our knowledge 
about the factors that contribute to acute postoperative 
pain and enhance our ability to detect clinical benefits 
associated with blockade of noxious perioperative inputs. 
Future work should focus on maximizing the prevention 
of surgically induced sensitization by ensuring as com-
plete a blockade as possible of nociceptive transmission 
throughout the three phases of the perioperative period. 
Long-term follow-up studies are needed to assess the 
efficacy of the perioperative interventions and to ascertain 
the true incidence of chronic post-surgical pain. 
Given the prominent role of psychosocial factors in 
chronic pain219 and the recent recommendations for 
assessment of core measures and domains in clinical 
trials,220 relevant psychological, emotional, and physical 
variables should be added to those foutinely assessed 
before and after surgery. Assessment of additional 
domains of functioning may help to shed light on the 
predictors of severe acute postoperative pain, the pro-
cesses involved in recovery from surgery, and the risk 
factors for developing chronic postsurgical pain. 57 
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